MF研究者総覧

Researcher Database

Advance
Researchers' Page on researchmap
Last Updated :2024/07/29

Researcher Profile and Settings

Master

Affiliation (Master)

  • Faculty of Medicine　Specialized Medicine　Neurological Disorder

Affiliation (Master)

  • Faculty of Medicine　Specialized Medicine　Neurological Disorder

researchmap

Profile and Settings

Profile and Settings

  • Name (Japanese)

    Naoki

  • Name (Kana)

    Hashimoto

  • Name

    201301089996845410

Alternate Names

Achievement

Research Interests

  • social cognition   cognitive neuroscience   schizophrenia   

Research Areas

  • Life sciences / Psychiatry / schizophrenia

Research Experience

  • 2013 Hokkaido University

Education

  • 2006/04 - 2011/03  Hokkaido University  Graduate School of Medicine
  • 1996/04 - 2000/03  Hokkaido University  School of Medicine

Published Papers

  • Kentaro Morita, Kenichiro Miura, Atsuhito Toyomaki, Manabu Makinodan, Kazutaka Ohi, Naoki Hashimoto, Yuka Yasuda, Takako Mitsudo, Fumihiro Higuchi, Shusuke Numata, Akiko Yamada, Yohei Aoki, Hiromitsu Honda, Ryo Mizui, Masato Honda, Daisuke Fujikane, Junya Matsumoto, Naomi Hasegawa, Satsuki Ito, Hisashi Akiyama, Toshiaki Onitsuka, Yoshihiro Satomura, Kiyoto Kasai, Ryota Hashimoto
    JMIR Mental Health 11 e56668 - e56668 2024/05/30 
    Background Schizophrenia is a complex mental disorder characterized by significant cognitive and neurobiological alterations. Impairments in cognitive function and eye movement have been known to be promising biomarkers for schizophrenia. However, cognitive assessment methods require specialized expertise. To date, data on simplified measurement tools for assessing both cognitive function and eye movement in patients with schizophrenia are lacking. Objective This study aims to assess the efficacy of a novel tablet-based platform combining cognitive and eye movement measures for classifying schizophrenia. Methods Forty-four patients with schizophrenia, 67 healthy controls, and 41 patients with other psychiatric diagnoses participated in this study from 10 sites across Japan. A free-viewing eye movement task and 2 cognitive assessment tools (Codebreaker task from the THINC-integrated tool and the CognitiveFunctionTest app) were used for conducting assessments in a 12.9-inch iPad Pro. We performed comparative group and logistic regression analyses for evaluating the diagnostic efficacy of the 3 measures of interest. Results Cognitive and eye movement measures differed significantly between patients with schizophrenia and healthy controls (all 3 measures; P<.001). The Codebreaker task showed the highest classification effectiveness in distinguishing schizophrenia with an area under the receiver operating characteristic curve of 0.90. Combining cognitive and eye movement measures further improved accuracy with a maximum area under the receiver operating characteristic curve of 0.94. Cognitive measures were more effective in differentiating patients with schizophrenia from healthy controls, whereas eye movement measures better differentiated schizophrenia from other psychiatric conditions. Conclusions This multisite study demonstrates the feasibility and effectiveness of a tablet-based app for assessing cognitive functioning and eye movements in patients with schizophrenia. Our results suggest the potential of tablet-based assessments of cognitive function and eye movement as simple and accessible evaluation tools, which may be useful for future clinical implementation.
  • Toshinori Nakamura, Ryuji Furihata, Naomi Hasegawa, Fumitoshi Kodaka, Hiroyuki Muraoka, Kayo Ichihashi, Shinichiro Ochi, Shusuke Numata, Takashi Tsuboi, Manabu Makinodan, Hitoshi Iida, Toshiaki Onitsuka, Hiroko Kashiwagi, Masahiro Takeshima, Naoki Hashimoto, Tatsuya Nagasawa, Masahide Usami, Hirotaka Yamagata, Yoshikazu Takaesu, Kenichiro Miura, Junya Matsumoto, Kazutaka Ohi, Hisashi Yamada, Hikaru Hori, Ken Inada, Koichiro Watanabe, Ryota Hashimoto, Norio Yasui-Furukori
    BMC psychiatry 24 (1) 399 - 399 2024/05/29 
    BACKGROUND: To examine whether the "Effectiveness of Guideline for Dissemination and Education in psychiatric treatment (EGIUDE)" project affects the rate of prescriptions of hypnotic medication and the type of hypnotic medications prescribed among psychiatrists, for schizophrenia and major depressive disorder in Japan. METHODS: The EGUIDE project is a nationwide prospective study of evidence-based clinical guidelines for schizophrenia and major depressive disorder in Japan. From 2016 to 2021, clinical and prescribing data from patients discharged from hospitals participating in the EGUIDE project were used to examine hypnotic medication prescriptions The prescribing rate of hypnotics and the prescribing rate of each type of hypnotic (benzodiazepine receptor agonist, nonbenzodiazepine receptor agonist, melatonin receptor agonist, and orexin receptor antagonist) were compared among patients who had been prescribed medication by psychiatrists participating in the EGUIDE project and patients who had been prescribed medication by nonparticipating psychiatrists. Multivariate logistic regression analysis was performed to examine the effect of the EGUIDE project on the prescription of hypnotic medications. RESULTS: A total of 12,161 patients with schizophrenia and 6,167 patients with major depressive disorder were included. Psychiatrists participating in the EGUIDE project significantly reduced the rate of prescribing hypnotic medication and benzodiazepine receptor agonists for both schizophrenia (P < 0.001) and major depressive disorder (P < 0.001) patients. CONCLUSION: This is the first study to investigate the educational effects of guidelines for the treatment of psychiatric disorders on psychiatrists in terms of prescribing hypnotic medications to patients. The EGUIDE project may play an important role in reducing hypnotic medication prescription rates, particularly with respect to benzodiazepine receptor agonists. The results suggest that the EGUIDE project may result in improved therapeutic behavior.
  • Hisashi Akiyama, Ryo Okubo, Atsuhito Toyomaki, Akane Miyazaki, Sachiko Hattori, Mariko Nohara, Yohei Sasaki, Ryotaro Kubota, Hiroki Okano, Kanami Takahashi, Yumi Hasegawa, Izumi Wada, Takashi Uchino, Kazuyoshi Takeda, Satoru Ikezawa, Takahiro Nemoto, Yoichi M Ito, Naoki Hashimoto
    Asian Journal of Psychiatry 104003 - 104003 1876-2018 2024/03
  • Hirotaka Yamagata, Yuko Fujii, Shinichiro Ochi, Tomoe Seki, Naomi Hasegawa, Hisashi Yamada, Hikaru Hori, Kayo Ichihashi, Jun ichi Iga, Kazuyoshi Ogasawara, Naoki Hashimoto, Hitoshi Iida, Kazutaka Ohi, Takashi Tsuboi, Shusuke Numata, Akitoyo Hishimoto, Masahide Usami, Eiichi Katsumoto, Hiroyuki Muraoka, Yoshikazu Takaesu, Tatsuya Nagasawa, Hiroshi Komatsu, Kenichiro Miura, Junya Matsumoto, Ken Inada, Shin Nakagawa, Ryota Hashimoto
    Psychiatry Research Communications 4 (1) 2024/03 
    Reports on polypharmacy strategies for patients with schizophrenia and major depressive disorder (MDD) are scarce. The nationwide Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project has been used to train psychiatrists on the guidelines for treatment of schizophrenia and MDD. This study aimed to determine whether the EGUIDE program enabled more appropriate evidence-based treatment of outpatients with schizophrenia and MDD. The types and doses of all psychotropics were analyzed in 174 and 147 patients with schizophrenia and MDD, respectively, in 2018 before the EGUIDE program and in 2019 and 2020 after the program. There were no significant differences in the rate of monopharmacy with antipsychotics for schizophrenia; however, the prescriptions of first-generation antipsychotics, anticholinergics, and benzodiazepines for schizophrenia decreased significantly after the program. There were also no significant differences in antidepressant monopharmacy rates for MDD; however, the prescriptions of benzodiazepines in patients with MDD decreased significantly after the program. Significant positive correlations were found between the number of psychotropic prescriptions and dosage of benzodiazepines. In conclusion, the EGUIDE project has improved the prescribing behavior for outpatients with schizophrenia and depression. Therefore, the guideline training program may be useful for regulating the prescribing behavior among physicians.
  • Ryuichi Yamazaki, Junya Matsumoto, Satsuki Ito, Kiyotaka Nemoto, Masaki Fukunaga, Naoki Hashimoto, Fumitoshi Kodaka, Harumasa Takano, Naomi Hasegawa, Yuka Yasuda, Michiko Fujimoto, Hidenaga Yamamori, Yoshiyuki Watanabe, Kenichiro Miura, Ryota Hashimoto
    Neuropsychopharmacology reports 2024/02/13 
    Establishing a brain biomarker for schizophrenia is strongly desirable not only to support diagnosis by psychiatrists but also to help track the progressive changes in the brain over the course of the illness. A brain morphological signature of schizophrenia was reported in a recent study and is defined by clusters of brain regions with reduced volume in schizophrenia patients compared to healthy individuals. This signature was proven to be effective at differentiating patients with schizophrenia from healthy individuals, suggesting that it is a good candidate brain biomarker of schizophrenia. However, the longitudinal characteristics of this signature have remained unclear. In this study, we examined whether these changes occurred over time and whether they were associated with clinical outcomes. We found a significant change in the brain morphological signature in schizophrenia patients with more brain volume loss than the natural, age-related reduction in healthy individuals, suggesting that this change can capture a progressive morphological change in the brain. We further found a significant association between changes in the brain morphological signature and changes in the full-scale intelligence quotient (IQ). The patients with IQ improvement showed preserved brain morphological signatures, whereas the patients without IQ improvement showed progressive changes in the brain morphological signature, suggesting a link between potential recovery of intellectual abilities and the speed of brain pathology progression. We conclude that the brain morphological signature is a brain biomarker that can be used to evaluate progressive changes in the brain that are associated with cognitive impairment due to schizophrenia.
  • Takashi Miyakoshi, Shuhei Ishikawa, Ryo Okubo, Naoki Hashimoto, Norihiro Sato, Ichiro Kusumi, Yoichi M Ito
    Journal of psychiatric research 168 149 - 156 2023/10/27 
    Antipsychotic medications increase the risk of abnormal glucose metabolism. However, in clinical practice, it is difficult to predict this risk because it is affected by medication-related and background factors. This study aimed to identify the risk factors for abnormal glucose metabolism during antipsychotic treatment. We conducted a multicenter, prospective, cohort study in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Of these patients, those with prediabetes or possible diabetes were excluded. Finally, 706 patients were included in the analysis. The hazard ratio (HR) for each factor was calculated for events of progression to hyperglycemia using time-dependent Cox regression analysis stratified according to facility type and adjusted for available background and drug-related factors. Treatments with olanzapine (HR = 2.06, 95% confidence interval [CI] = 1.05-4.05), clozapine (HR = 4.25, 95% CI = 1.56-11.60), and chlorpromazine (HR = 4.48, 95% CI = 1.21-16.57), overweight and obesity (HR = 1.57, 95% CI = 1.02-2.41), and hypertriglyceridemia (HR = 1.72, 95% CI = 1.02-2.88) were associated with a significantly higher occurrence of hyperglycemic progression. The number and daily dose of antipsychotics were not associated with their occurrence. Our study demonstrated that more careful monitoring is necessary during olanzapine, clozapine, and chlorpromazine treatment because of the higher occurrence of abnormalities in glucose metabolism. Furthermore, patients with obesity or hypertriglyceridemia warrant monitoring for the occurrence of abnormal glucose metabolism, regardless of the type of antipsychotic medication.
  • Takashi Ozaki, Naoki Hashimoto, Niki Udo, Hisashi Narita, Shin Nakagawa, Ichiro Kusumi
    Psychogeriatrics 1346-3500 2023/10/08 
    Background Alzheimer's disease (AD) dementia and mild cognitive impairment are characterised by impaired cognition accompanied by neuropsychiatric symptoms (NPS) relating to mood, including depression, anxiety, and apathy. However, the utility of AD biomarkers for predicting mood symptoms of NPS remains controversial. Herein, we analyzed the relationship between phosphorylated tau (p‐tau) and depression, anxiety, and apathy of NPS. We also examined the influence of genetic factors such as apolipoprotein E (APOE) ε4 on these relationships. Methods We conducted a cross‐sectional survey in older patients (n = 122) with normal cognition (n = 12), mild cognitive impairment (n = 46), and AD (n = 64) strictly diagnosed by the board of psychiatrists and neurologists of Hokkaido University. NPS of the patients were assessed using the Neuropsychiatric Inventory Questionnaire (NPI). All patients also received a lumbar puncture to obtain cerebral spinal fluid for assessment of p‐tau. The inverse probability weighting method was used to adjust for demographic differences between the p‐tau present group and the p‐tau absent group. Results There was an association between p‐tau accumulation and decreased incidence of depression and apathy. APOE ε4 non‐carriers also showed a trend toward a negative association between p‐tau and depression, which was not evident in APOE ε4 carriers. Conclusions We provide new evidence for a negative correlation between p‐tau and depression and apathy of NPS, which may be influenced by APOE ε4. Future longitudinal studies are required to confirm the utility of p‐tau for predicting the course of mood symptoms in patients with cognitive decline.
  • Yukiko Ogura, Yumi Wakatsuki, Naoki Hashimoto, Tamaki Miyamoto, Yukiei Nakai, Atsuhito Toyomaki, Yukio Tsuchida, Shin Nakagawa, Takeshi Inoue, Ichiro Kusumi
    Psychiatry and Clinical Neurosciences Reports 2 (3) 2769-2558 2023/09/13 
    Abstract Aim Hyperthymic temperament is a cheerful action orientation that is suggested to have a protective effect on depressive symptoms. We recently reported that hyperthymic temperament can positively predict activation of reward‐related brain areas in anticipation of monetary rewards, which could serve as a biomarker of hyperthymic temperament. However, the relationship between hyperthymic temperament and neural responsiveness to nonmonetary rewards (i.e., feedback indicating success in a task) remains unclear. Methods Healthy participants performed a modified monetary incentive delay task inside a functional magnetic resonance imaging scanner. To examine the effect of nonmonetary positive feedback, the participants performed feedback and no‐feedback trials. We explored brain regions whose neural responsiveness to nonmonetary rewards was predicted by hyperthymic temperament. Results There was premotor area activation in anticipation of a nonmonetary reward, which was negatively predicted by hyperthymic temperament. Moreover, brain areas located mainly in the primary somatosensory area and somatosensory association area were activated by performance feedback, which was positively predicted by hyperthymic temperament. Conclusion We found that hyperthymic temperament is related to neural responsiveness to both monetary and nonmonetary rewards. This may be related to the process of affective regulation in the somatosensory area.
  • Naomi Hasegawa, Yuka Yasuda, Norio Yasui-Furukori, Hisashi Yamada, Hikaru Hori, Kayo Ichihashi, Yoshikazu Takaesu, Hitoshi Iida, Hiroyuki Muraoka, Fumitoshi Kodaka, Jun-Ichi Iga, Naoki Hashimoto, Kazuyoshi Ogasawara, Kazutaka Ohi, Kentaro Fukumoto, Shusuke Numata, Takashi Tsuboi, Masahide Usami, Akitoyo Hishimoto, Ryuji Furihata, Taishiro Kishimoto, Toshinori Nakamura, Eiichi Katsumoto, Shinichiro Ochi, Tatsuya Nagasawa, Kiyokazu Atake, Chika Kubota, Hiroshi Komatsu, Hirotaka Yamagata, Kenta Ide, Masahiro Takeshima, Mikio Kido, Saya Kikuchi, Tsuyoshi Okada, Junya Matsumoto, Kenichiro Miura, Taichi Shimazu, Ken Inada, Koichiro Watanabe, Ryota Hashimoto
    Psychiatry and clinical neurosciences 2023/09/08 
    AIM: This study aims to examine the real-world effectiveness of education regarding clinical guidelines for psychiatric disorders using 'the Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)' project. METHODS: The EGUIDE project is a nationwide prospective implementation study of two clinical practice guidelines, i.e., the Guideline for Pharmacological Therapy of Schizophrenia and the Treatment Guidelines for Major Depressive Disorders, in Japan. Between 2016 and 2019, 782 psychiatrists belonging to 176 hospitals with psychiatric wards participated in the project and attended lectures on clinical practice guidelines. The proportions of guideline-recommended treatments in 7405 patients with schizophrenia and 3794 patients with major depressive disorder at participating hospitals were compared between patients under the care of psychiatrists participating in the project and those not participating in the project. Clinical and prescribing data on the patients discharged from April to September each year from participating hospitals of the project were also analyzed. RESULTS: The proportions of three quality indicators (antipsychotic monotherapy regardless of whether other psychotropics medication, antipsychotic monotherapy without other psychotropics and no prescription of anxiolytics or hypnotics) for schizophrenia were higher among participating psychiatrists than among nonparticipating psychiatrists. As similar results were obtained in major depressive disorder, the effectiveness of the project for the dissemination of guideline-recommended treatment has been replicated. CONCLUSION: This strategy of providing education regarding the clinical guidelines for psychiatric disorders was effective in improving the treatment-related behavior of psychiatrists. The use of this education-based strategy might contribute to resolving the mental health treatment gap.
  • クロザピン誘発発作に対する抗痙攣薬の使用 統合失調症患者における後ろ向き研究(Use of Anti-Seizure Medications for Clozapine-Induced Seizures: A Retrospective Study in Patients with Schizophrenia)
    堀之内 徹, 中村 悠一, 石川 修平, 橋本 直樹, 成田 尚, 三井 信幸, 賀古 勇輝, 久住 一郎
    てんかん研究 41 (2) 319 - 319 0912-0890 2023/09
  • Junya Matsumoto, Masaki Fukunaga, Kenichiro Miura, Kiyotaka Nemoto, Naohiro Okada, Naoki Hashimoto, Kentaro Morita, Daisuke Koshiyama, Kazutaka Ohi, Tsutomu Takahashi, Michihiko Koeda, Hidenaga Yamamori, Michiko Fujimoto, Yuka Yasuda, Satsuki Ito, Ryuichi Yamazaki, Naomi Hasegawa, Hisashi Narita, Satoshi Yokoyama, Ryo Mishima, Jun Miyata, Yuko Kobayashi, Daiki Sasabayashi, Kenichiro Harada, Maeri Yamamoto, Yoji Hirano, Takashi Itahashi, Masahito Nakataki, Ryu-ichiro Hashimoto, Khin K. Tha, Shinsuke Koike, Toshio Matsubara, Go Okada, Reiji Yoshimura, Osamu Abe, Theo G. M. van Erp, Jessica A. Turner, Neda Jahanshad, Paul M. Thompson, Toshiaki Onitsuka, Yoshiyuki Watanabe, Koji Matsuo, Hidenori Yamasue, Yasumasa Okamoto, Michio Suzuki, Norio Ozaki, Kiyoto Kasai, Ryota Hashimoto
    Molecular Psychiatry 1359-4184 2023/08/18 
    Abstract According to the operational diagnostic criteria, psychiatric disorders such as schizophrenia (SZ), bipolar disorder (BD), major depressive disorder (MDD), and autism spectrum disorder (ASD) are classified based on symptoms. While its cluster of symptoms defines each of these psychiatric disorders, there is also an overlap in symptoms between the disorders. We hypothesized that there are also similarities and differences in cortical structural neuroimaging features among these psychiatric disorders. T1-weighted magnetic resonance imaging scans were performed for 5,549 subjects recruited from 14 sites. Effect sizes were determined using a linear regression model within each protocol, and these effect sizes were meta-analyzed. The similarity of the differences in cortical thickness and surface area of each disorder group was calculated using cosine similarity, which was calculated from the effect sizes of each cortical regions. The thinnest cortex was found in SZ, followed by BD and MDD. The cosine similarity values between disorders were 0.943 for SZ and BD, 0.959 for SZ and MDD, and 0.943 for BD and MDD, which indicated that a common pattern of cortical thickness alterations was found among SZ, BD, and MDD. Additionally, a generally smaller cortical surface area was found in SZ and MDD than in BD, and the effect was larger in SZ. The cosine similarity values between disorders were 0.945 for SZ and MDD, 0.867 for SZ and ASD, and 0.811 for MDD and ASD, which indicated a common pattern of cortical surface area alterations among SZ, MDD, and ASD. Patterns of alterations in cortical thickness and surface area were revealed in the four major psychiatric disorders. To our knowledge, this is the first report of a cross-disorder analysis conducted on four major psychiatric disorders. Cross-disorder brain imaging research can help to advance our understanding of the pathogenesis of psychiatric disorders and common symptoms.
  • Yumi Aoki, Yoshikazu Takaesu, Kentaro Matsui, Takahiro Tokumasu, Hideaki Tani, Yoshiteru Takekita, Tetsufumi Kanazawa, Taishiro Kishimoto, Seiichiro Tarutani, Naoki Hashimoto, Hiroyoshi Takeuchi, Kazuo Mishima, Ken Inada
    Neuropsychopharmacology reports 43 (3) 391 - 402 2023/07/14 
    AIM: Continued antipsychotic treatment is the key to preventing relapse. Maintenance antipsychotic monotherapy and optimal dose use are recommended for individuals with stable schizophrenia because of their undesirable effects. Decision aids (DAs) are clinical conversation tools that facilitate shared decision-making (SDM) between patients and health-care providers. This study aimed to describe the development process and results of acceptability testing of a DA for individuals with stable schizophrenia, considering (i) whether to continue high-dose antipsychotics or reduce to the standard dose and (ii) whether to continue two antipsychotics or shift to monotherapy. METHODS: A DA was developed according to the guidelines for the appropriate use of psychotropic medications and International Patient Decision Aid Standards (IPDAS). First, a DA prototype was developed based on a previous systematic review and meta-analysis conducted for identifying the effects of continuing or reducing antipsychotic treatment. Second, mixed-method survey was performed among individuals with schizophrenia and health-care providers to modify and finalize the DA. RESULTS: The DA consisted of an explanation of schizophrenia, options to continue high-dose antipsychotics or reduce to the standard dose, options to continue two antipsychotics or shift to monotherapy, pros and cons of each option, and a value-clarification worksheet for each option. The patients (n = 20) reported acceptable language use (75%), adequate information (75%), and well-balanced presentation (79%). Health-care providers (n = 20) also provided favorable overall feedback. The final DA covered six IPDAS qualifying criteria. CONCLUSION: A DA was successfully developed for schizophrenia, considering whether to reduce antipsychotics, which can be used in the SDM process.
  • 4大精神疾患の大脳構造の類似度の解析 大脳皮質厚と大脳皮質表面積の多施設共同疾患横断解析
    松本 純弥, 福永 雅喜, 三浦 健一郎, 根本 清貴, 岡田 直大, 橋本 直樹, 森田 健太郎, 越山 太輔, 大井 一高, 高橋 努, 肥田 道彦, 山森 英長, 藤本 美智子, 安田 由華, 伊藤 颯姫, 山崎 龍一, 長谷川 尚美, 成田 尚, 横山 仁史, 三嶋 亮, 宮田 淳, 小林 祐子, 笹林 大樹, 原田 健一郎, 山本 真江里, 平野 羊嗣, 板橋 貴史, 中瀧 理仁, 橋本 龍一郎, タ・キンキン, 小池 進介, 松原 敏郎, 岡田 剛, 吉村 玲児, 阿部 修, 鬼塚 俊明, 渡邊 嘉之, 松尾 幸治, 山末 英典, 岡本 泰昌, 鈴木 道雄, 尾崎 紀夫, 笠井 清登, 橋本 亮太
    国立精神・神経医療研究センター精神保健研究所年報 (国研)国立精神・神経医療研究センター精神保健研究所 (36) 210 - 210 2023/07
  • 4大精神疾患の大脳構造の類似度の解析 大脳皮質厚と大脳皮質表面積の多施設共同疾患横断解析
    松本 純弥, 福永 雅喜, 三浦 健一郎, 根本 清貴, 岡田 直大, 橋本 直樹, 森田 健太郎, 越山 太輔, 大井 一高, 高橋 努, 肥田 道彦, 山森 英長, 藤本 美智子, 安田 由華, 伊藤 颯姫, 山崎 龍一, 長谷川 尚美, 成田 尚, 横山 仁史, 三嶋 亮, 宮田 淳, 小林 祐子, 笹林 大樹, 原田 健一郎, 山本 真江里, 平野 羊嗣, 板橋 貴史, 中瀧 理仁, 橋本 龍一郎, タ・キンキン, 小池 進介, 松原 敏郎, 岡田 剛, 吉村 玲児, 阿部 修, 鬼塚 俊明, 渡邊 嘉之, 松尾 幸治, 山末 英典, 岡本 泰昌, 鈴木 道雄, 尾崎 紀夫, 笠井 清登, 橋本 亮太
    国立精神・神経医療研究センター精神保健研究所年報 (国研)国立精神・神経医療研究センター精神保健研究所 (36) 210 - 210 2023/07
  • Naoki Hashimoto, Norio Yasui-Furukori, Naomi Hasegawa, Shuhei Ishikawa, Hikaru Hori, Hitoshi Iida, Kayo Ichihashi, Kenichiro Miura, Junya Matsumoto, Shusuke Numata, Fumitoshi Kodaka, Ryuji Furihata, Kazutaka Ohi, Kazuyoshi Ogasawara, Jun-Ichi Iga, Hiroyuki Muraoka, Hiroshi Komatsu, Masahiro Takeshima, Kiyokazu Atake, Mikio Kido, Toshinori Nakamura, Taishiro Kishimoto, Akitoyo Hishimoto, Toshiaki Onitsuka, Tsuyoshi Okada, Shinichiro Ochi, Tatsuya Nagasawa, Manabu Makinodan, Hiroki Yamada, Takashi Tsuboi, Hisashi Yamada, Ken Inada, Koichiro Watanabe, Ryota Hashimoto
    BMC psychiatry 23 (1) 473 - 473 2023/06/28 
    BACKGROUND: Polypharmacy of additional psychotropics alongside the main treatment drug (antipsychotics in schizophrenia and antidepressants in major depressive disorder) is common in Japan. Our goal is to align psychotropic prescription in Japan with international standards, while reducing the differences between facilities. To achieve this goal, we aimed to compare prescriptions at the time of hospital admission and discharge. METHODS: Data on prescriptions at admission and discharge from 2016 to 2020 were collected. We divided the patients into four groups: (1) mono_mono group, monotherapy of the main drug at admission and discharge; (2) mono_poly group, monotherapy at admission and polypharmacy at discharge; (3) poly_poly group, polypharmacy at admission and discharge; and (4) poly_mono group, polypharmacy at admission and monotherapy at discharge. We compared the changes in dosage and number of psychotropics among the four groups. RESULTS: For both schizophrenia and major depressive disorder, the patients who received monotherapy with the main drug at admission were likely to receive main drug monotherapy at discharge and vice versa. For schizophrenia, the polypharmacy was prescribed more often in the mono_poly group than that in the mono_mono group. The prescription was not changed at all for more than 10% of the patients. CONCLUSIONS: It is critical to avoid a polypharmacy regimen to ensure that guideline-compliant treatment is provided. We expect higher rates of monotherapy with the main drug after the EGUIDE lectures. TRIAL REGISTRATION: The study protocol was registered in the University Hospital Medical Information Network Registry (UMIN000022645).
  • 多施設共同研究による統合失調症と双極性障害の大脳皮質構造画像解析
    松本 純弥, 福永 雅喜, 三浦 健一郎, 岡田 直大, 根本 清貴, 藤本 美智子, 肥田 道彦, 宮田 淳, 大井 一高, 中瀧 理仁, 吉村 玲児, 岡本 泰昌, 原田 健一郎, 橋本 直樹, 鬼塚 俊明, 山本 真江里, 山末 英典, 高橋 努, 渡邊 嘉之, 笠井 清登, 橋本 亮太
    精神神経学雑誌 (公社)日本精神神経学会 (2023特別号) S398 - S398 0033-2658 2023/06
  • Takashi Uchino, Ryo Okubo, Youji Takubo, Akiko Aoki, Izumi Wada, Naoki Hashimoto, Satoru Ikezawa, Takahiro Nemoto
    Journal of personalized medicine 13 (4) 2023/04/19 
    BACKGROUND: In schizophrenia spectrum disorders (SSD), social cognition mediates the relationship between neurocognition and social functioning. Although people with major depressive disorder (MDD) also exhibit cognitive impairments, which are often prolonged, little is known about the role of social cognition in MDD. METHODS: Using data obtained through an internet survey, 210 patients with SSD or MDD were selected using propensity score matching based on their demographics and illness duration. Social cognition, neurocognition, and social functioning were evaluated using the Self-Assessment of Social Cognition Impairments, Perceived Deficits Questionnaire, and Social Functioning Scale, respectively. The mediation effects of social cognition on the relationship between neurocognition and social functioning were examined in each group. Invariances of the mediation model across the two groups were then analyzed. RESULTS: The SSD and MDD groups had mean ages of 44.49 and 45.35 years, contained 42.0% and 42.8% women, and had mean illness durations of 10.76 and 10.45 years, respectively. In both groups, social cognition had significant mediation effects. Configural, measurement, and structural invariances across the groups were established. CONCLUSION: The role of social cognition in patients with MDD was similar to that in SSD. Social cognition could be a common endophenotype for various psychiatric disorders.
  • Ryota Hashimoto, Naohiro Okada, Masaki Fukunaga, Kenichiro Miura, Kiyotaka Nemoto, Junya Matsumoto, Naoki Hashimoto, Masahiro Kiyota, Kentaro Morita, Daisuke Koshiyama, Kazutaka Ohi, Tsutomu Takahashi, Michihiko Koeda, Hidenaga Yamamori, Michiko Fujimoto, Yuka Yasuda, Naomi Hasegawa, Hisashi Narita, Satoshi Yokoyama, Ryo Mishima, Takahiko Kawashima, Yuko Kobayashi, Daiki Sasabayashi, Kenichiro Harada, Maeri Yamamoto, Yoji Hirano, Takashi Itahashi, Masahito Nakataki, Ryuichiro Hashimoto, Khin Tha, Shinsuke Koike, Toshio Matsubara, Go Okada, Theo van Erp, Neda Jahanshad, Reiji Yoshimura, Osamu Abe, Toshiaki Onitsuka, Yoshiyuki Watanabe, Koji Matsuo, Hidenori Yamasue, Yasumasa Okamoto, Michio Suzuki, Jessica Turner, Paul Thompson, Norio Ozaki, Kiyoto Kasai
    2023/01/04
  • Kazuyuki Nakagome, Manabu Makinodan, Mitsuhiro Uratani, Masaki Kato, Norio Ozaki, Seiko Miyata, Kunihiro Iwamoto, Naoki Hashimoto, Atsuhito Toyomaki, Kazuo Mishima, Masaya Ogasawara, Masahiro Takeshima, Kazumichi Minato, Toshikazu Fukami, Mari Oba, Kazuyoshi Takeda, Hideki Oi
    Frontiers in psychiatry 14 1189765 - 1189765 2023 
    OBJECT: Real-world data from wearable devices has the potential to understand mental health status in everyday life. We aimed to investigate the feasibility of estimating mental health status using a wrist-worn wearable device (Fitbit Sense) that measures movement using a 3D accelerometer and optical pulse photoplethysmography (PPG). METHODS: Participants were 110 patients with mental illnesses from different diagnostic groups. The study was undertaken between 1 October 2020 and 31 March 2021. Participants wore a Fitbit Sense on their wrist and also completed the State-Trait Anxiety Inventory (STAI), Positive and Negative Affect Schedule (PANAS), and EuroQol 5 dimensions 5-level (EQ-5D-5L) during the study period. To determine heart rate (HR) variability (HRV), we calculated the sdnn (standard deviation of the normal-to-normal interval), coefficient of variation of R-R intervals, and mean HR separately for each sleep stage and the daytime. The association between mental health status and HR and HRV was analyzed. RESULTS: The following significant correlations were found in the wake after sleep onset stage within 3 days of mental health status assessment: sdnn, HR and STAI scores, HR and PANAS scores, HR and EQ-5D-5L scores. The association between mental health status and HR and HRV was stronger the closer the temporal distance between mental health status assessment and HR measurement. CONCLUSION: A wrist-worn wearable device that measures PPG signals was feasible for use with patients with mental illness. Resting state HR and HRV could be used as an objective assessment of mental health status within a few days of measurement.
  • Yoshitaka Kyou, Norio Yasui-Furukori, Naomi Hasegawa, Kenta Ide, Kayo Ichihashi, Naoki Hashimoto, Hikaru Hori, Yoshihito Shimizu, Yayoi Imamura, Hiroyuki Muraoka, Hitoshi Iida, Kazutaka Ohi, Yuka Yasuda, Kazuyoshi Ogasawara, Shusuke Numata, Jun-Ichi Iga, Takashi Tsuboi, Shinichiro Ochi, Fumitoshi Kodaka, Ryuji Furihata, Toshiaki Onitsuka, Manabu Makinodan, Hiroshi Komatsu, Masahiro Takeshima, Chika Kubota, Akitoyo Hishimoto, Kiyokazu Atake, Hirotaka Yamagata, Mikio Kido, Tatsuya Nagasawa, Masahide Usami, Taishiro Kishimoto, Saya Kikuchi, Junya Matsumoto, Kenichiro Miura, Hisashi Yamada, Koichiro Watanabe, Ken Inada, Ryota Hahimoto
    Annals of general psychiatry 21 (1) 52 - 52 2022/12/26 
    BACKGROUND: Several guidelines recommend monotherapy in pharmacotherapy for schizophrenia and major depressive disorder. The content of regular prescriptions has been reported in several studies, but not enough research has been conducted on the content of pharmacotherapy, including pro re nata (PRN) medications. The purpose of this study was to evaluate the content of pharmacotherapy, including PRN medications, and to clarify the relationship with regular prescriptions. METHODS: We used data from the "Effectiveness of Guidelines for Dissemination And Education in psychiatric treatment" (EGUIDE) project to investigate the presence or absence of PRN psychotropic medications at discharge for each drug category. We compared the PRN psychotropic prescription ratio at discharge by diagnosis for each drug category. The antipsychotic monotherapy ratio and no prescription ratio of other psychotropics for schizophrenia at discharge and the antidepressant monotherapy ratio and no prescription ratio of other psychotropics for major depressive disorder at discharge were calculated for each regular prescription, including PRN psychotropic medications, as quality indicators (QIs). Spearman's rank correlation test was performed for QI values of regular prescriptions and the QI ratio between regular prescriptions and prescriptions including PRN medications for each diagnosis. RESULTS: The PRN psychotropic prescription ratio at discharge was 28.7% for schizophrenia and 30.4% for major depressive disorder, with no significant differences by diagnosis. The prescription ratios of PRN antipsychotic medications and PRN antiparkinsonian medications were significantly higher for schizophrenia. The prescription ratios of PRN anxiolytic and hypnotic and PRN antidepressant medications were significantly higher for patients with major depressive disorder. For both schizophrenia and major depressive disorder, the QI was lower for discharge prescriptions, including PRN medications, than for regular prescriptions. QI values for regular prescriptions and the QI ratio were positively correlated. CONCLUSIONS: Considering PRN psychotropic medications, the monotherapy ratio and no prescription ratio of other psychotropics at discharge decreased in pharmacotherapy for schizophrenia and major depressive disorder. A higher ratio of monotherapy and no prescription of other psychotropics on regular prescriptions may result in less concomitant use of PRN psychotropic medications. Further studies are needed to optimize PRN psychotropic prescriptions.
  • Hitoshi Iida, Tsuyoshi Okada, Kiyotaka Nemoto, Naomi Hasegawa, Shusuke Numata, Kazuyoshi Ogasawara, Kenichiro Miura, Junya Matsumoto, Hikaru Hori, Jun-Ichi Iga, Kayo Ichihashi, Naoki Hashimoto, Hisashi Yamada, Kazutaka Ohi, Norio Yasui-Furukori, Kentaro Fukumoto, Takashi Tsuboi, Masahide Usami, Ryuji Furihata, Yoshikazu Takaesu, Akitoyo Hishimoto, Hiroyuki Muraoka, Eiichi Katsumoto, Tatsuya Nagasawa, Shinichiro Ochi, Hiroshi Komatsu, Saya Kikuchi, Masahiro Takeshima, Toshiaki Onitsuka, Shinichiro Tamai, Chika Kubota, Ken Inada, Koichiro Watanabe, Hiroaki Kawasaki, Ryota Hashimoto
    Neuropsychopharmacology reports 43 (1) 23 - 32 2022/11/28 [Refereed][Not invited]
     
    To disseminate, educate, and validate psychiatric clinical practice guidelines, the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project was launched in 2016. In this study, we investigated whether the web-based courses offered by this project would be as effective as the face-to-face courses. We analyzed and compared survey answers about overall participant satisfaction with the course and answers regarding clinical knowledge of schizophrenia and major depressive disorder between 170 participants who took the web-based courses in 2020 and 689 participants who took the face-to-face courses from 2016 to 2019. The web-based course participants completed the survey questions about satisfaction with the web-based courses. The web-based courses were conducted using a combination of web services to make it as similar as possible to the face-to-face courses. The degree of satisfaction assessed by the general evaluation of the web-based courses was higher than what was expected from the face-to-face courses. The degree of satisfaction was similar for the courses on schizophrenia and major depressive disorder. In addition, there were no significant differences in overall satisfaction and clinical knowledge between web-based and face-to-face courses. In conclusion, the web-based courses on clinical practice guidelines provided by the EGUIDE project were rated as more satisfying than the face-to-face course that the participants expected to take and no differences in the effectiveness of either course. The results suggest that, after the COVID-19 pandemic, it would be possible to disseminate this educational material more widely by adopting web-based courses additionally face-to-face courses.
  • Kentaro Fukumoto, Fumitoshi Kodaka, Naomi Hasegawa, Hiroyuki Muraoka, Hikaru Hori, Kayo Ichihashi, Yuka Yasuda, Hitoshi Iida, Kazutaka Ohi, Shinichiro Ochi, Kenta Ide, Naoki Hashimoto, Masahide Usami, Toshinori Nakamura, Hiroshi Komatsu, Tsuyoshi Okada, Tatsuya Nagasawa, Ryuji Furihata, Kiyokazu Atake, Mikio Kido, Saya Kikuchi, Hirotaka Yamagata, Taishiro Kishimoto, Manabu Makinodan, Tadasu Horai, Masahiro Takeshima, Chika Kubota, Takeshi Asami, Eiichi Katsumoto, Akitoyo Hishimoto, Toshiaki Onitsuka, Junya Matsumoto, Kenichiro Miura, Hisashi Yamada, Norio Yasui-Furukori, Koichiro Watanabe, Ken Inada, Kotaro Otsuka, Ryota Hashimoto
    Neuropsychopharmacology reports 43 (1) 33 - 39 2022/11/16 
    AIM: Treatment guidelines are designed to assist patients and health care providers and are used as tools for making treatment decisions in clinical situations. The treatment guidelines of the Japanese Society of Mood Disorders establish treatment recommendations for each severity of depression. The individual fitness score (IFS) was developed as a simple and objective indicator to assess whether individual patients are practicing treatment by the recommendations of the depression treatment guidelines of the Japanese Society of Mood Disorders. METHODS: The EGUIDE project members determined the IFS through the modified Delphi method. In this article, the IFS was calculated based on the treatment of depressed patients treated and discharged between 2016 and 2020 at facilities participating in the EGUIDE project. In addition, we compared scores at admission and discharge. RESULTS: The study included 428 depressed patients (mild n = 22, moderate/severe n = 331, psychotic n = 75) at 57 facilities. The mean IFS scores by severity were statistically significantly higher at discharge than at admission with moderate/severe depression (mild 36.1 ± 34.2 vs. 41.6 ± 36.9, p = 0.49; moderate/severe 50.2 ± 33.6 vs. 55.7 ± 32.6, p = 2.1 × 10-3; psychotic 47.4 ± 32.9 versus 52.9 ± 36.0, p = 0.23). CONCLUSION: We developed the IFS based on the depression treatment guideline, which enables us to objectively determine how close the treatment is to the guideline at the time of evaluation in individual cases. Therefore, the IFS may influence guideline-oriented treatment behavior and lead to the equalization of depression treatment in Japan, including pharmacotherapy.
  • Ken Inada, Kentaro Fukumoto, Naomi Hasegawa, Yuka Yasuda, Hisashi Yamada, Hikaru Hori, Kayo Ichihashi, Hitoshi Iida, Kazutaka Ohi, Hiroyuki Muraoka, Fumitoshi Kodaka, Kenta Ide, Naoki Hashimoto, Jun-Ichi Iga, Kazuyoshi Ogasawara, Kiyokazu Atake, Yoshikazu Takaesu, Tatsuya Nagasawa, Hiroshi Komatsu, Tsuyoshi Okada, Ryuji Furihata, Mikio Kido, Saya Kikuchi, Chika Kubota, Manabu Makinodan, Shinichiro Ochi, Masahiro Takeshima, Hirotaka Yamagata, Junya Matsumoto, Kenichiro Miura, Masahide Usami, Taishiro Kishimoto, Toshiaki Onitsuka, Eiichi Katsumoto, Akitoyo Hishimoto, Shusuke Numata, Norio Yasui-Furukori, Koichiro Watanabe, Ryota Hashimoto
    Neuropsychopharmacology reports 42 (4) 502 - 509 2022/10/18 
    AIMS: The Guidelines for the Pharmacotherapy of Schizophrenia were established to improve the quality of medical care, and the EGUIDE project was conducted to train clinicians on guideline usage. A quality indicator (QI) was established to measure the prevalence of the guidelines, and a survey was conducted, which revealed a gap between the guidelines and actual clinical practice (evidence-practice-gap). The purpose of this study was to develop an individual fitness score (IFS) formula that expresses the degree to which prescribers adhere to the Guidelines for Pharmacological Therapy of Schizophrenia in a simple manner, and to determine the validity of this formula from a survey of the prescriptions of the EGUIDE project participants'. METHODS: To establish appropriate scores, members discussed the proposed formula and then voted on them. The IFS formula developed was set up so that antipsychotic monotherapy would be given 100 points, with points deducted if concomitant or adjunctive antipsychotic medications were used, and a minimum score of 0. To validate this formula, prescriptions of hospitalized schizophrenic patients at admission and at discharge were scored and compared. RESULT: IFS points vary and ranged from 0 to100. The average pre-admission score for all subjects was 45.6, and the average score at discharge was 54, those were significantly higher during discharge. CONCLUSIONS: We developed an IFS formula, a tool to easily visualize the degree to which current prescriptions conform to the guidelines for the pharmacological treatment of schizophrenia.
  • Keisuke Takanobu, Naoki Hashimoto, Shuhei Ishikawa, Ichiro Kusumi
    BMJ case reports 15 (10) 2022/10/13 
    Clozapine is the only drug with confirmed efficacy for refractory schizophrenia; however, its use is restricted due to the risk of potentially life-threatening side effects, such as agranulocytosis. Although this restriction ensures safety against haematological risks, some patients with refractory schizophrenia who have low neutrophil levels may miss the opportunity to receive clozapine treatment. We herein report the case of a patient with refractory schizophrenia and low neutrophil levels who was successfully initiated on clozapine treatment after the use of several methods for increasing neutrophil levels. These strategies consisted of discontinuation of antipsychotics, treatment with lithium carbonate and adenine, and light exercise before blood testing. Combining these procedures may be an effective option in the treatment of patients with refractory schizophrenia whose neutrophil levels are not sufficient to initiate clozapine.
  • Takashi Tsuboi, Yoshikazu Takaesu, Naomi Hasegawa, Shinichiro Ochi, Kentaro Fukumoto, Kazutaka Ohi, Hiroyuki Muraoka, Tsuyoshi Okada, Funitoshi Kodaka, Shun Igarashi, Hitoshi Iida, Hiroko Kashiwagi, Hikaru Hori, Kayo Ichihashi, Kazuyoshi Ogasawara, Naoki Hashimoto, Jun-Ichi Iga, Toshinori Nakamura, Masahide Usami, Tatsuya Nagasawa, Mikio Kido, Hiroshi Komatsu, Hirotaka Yamagata, Kiyokazu Atake, Ryuji Furihata, Saya Kikuchi, Tadasu Horai, Masahiro Takeshima, Yoji Hirano, Manabu Makinodan, Junya Matsumoto, Kenichiro Miura, Akitoyo Hishimoto, Shusuke Numata, Hisashi Yamada, Norio Yasui-Furukori, Ken Inada, Koichiro Watanabe, Ryota Hashimoto
    Psychiatry and clinical neurosciences 77 (1) 30 - 37 2022/10/10 
    AIM: We investigated the association of electroconvulsive therapy (ECT) with anxiolytic and sleep medication use in patients with major depressive disorder (MDD) and schizophrenia (SZ). METHODS: This nationwide observational study analyzed data from 3483 MDD inpatients and 6663 SZ inpatients. Patients with MDD and SZ were classified into those who underwent ECT during hospitalization and those who did not. A propensity score-matching method was performed to adjust for preadmission characteristics and clinical information, which were expected bias between the two groups. Rates of anxiolytic and sleep medication use at discharge were compared in the matched sample. RESULTS: 500 MDD patients were assigned to both groups. In the matched MDD sample, the rate of anxiolytic and sleep medication use at discharge was significantly lower in the ECT group than in the non-ECT group (64.9% vs. 75.8%, P = 1.7 × 10-4 ). In the ECT group, the rate of anxiolytic and sleep medication use at discharge was significantly lower than that prior to admission (64.9% vs. 73.2%, P = 1.2 × 10-14 ). 390 SZ patients were allocated. In the matched SZ sample, the ECT group was not significantly different from the non-ECT group in the rate of anxiolytics and sleep medications use at discharge (61.3% vs. 68.2%, P = 4.3 × 10-2 ). In the ECT group, the rate of anxiolytics and sleep medications use at discharge was significantly lower than that before admission (61.3% vs. 70.5%, P = 4.4 × 10-4 ), although this was not the primary outcome. CONCLUSION: Reduction of anxiolytic and sleep medication use may be considered positively when ECT is indicated for treatment of MDD.
  • Tsuyoshi Okada, Hikaru Hori, Naomi Hasegawa, Atsunobu Murata, Yoshitaka Kyou, Fumitoshi Kodaka, Hitoshi Iida, Shinichiro Ochi, Yoshikazu Takaesu, Takashi Tsuboi, Jun-Ichi Iga, Kayo Ichihashi, Hiroyuki Muraoka, Ryuji Furihata, Norio Yasui-Furukori, Masahide Usami, Toshiaki Onitsuka, Kazuyoshi Ogasawara, Hiromi Tagata, Masahiro Takeshima, Kazutaka Ohi, Shusuke Numata, Naoki Hashimoto, Hiroki Yamada, Manabu Makinodan, Hiroshi Komatsu, Akitoyo Hishimoto, Hirotaka Yamagata, Mikio Kido, Chika Kubota, Kiyokazu Atake, Hisashi Yamada, Tatsuya Nagasawa, Junya Matsumoto, Kenichiro Miura, Ken Inada, Koichiro Watanabe, Shiro Suda, Ryota Hashimoto
    Journal of clinical psychopharmacology 2022/10/04 [Refereed][Not invited]
  • Yukiko Ogura, Yumi Wakatsuki, Naoki Hashimoto, Tamaki Miyamoto, Yukiei Nakai, Atsuhito Toyomaki, Yukio Tsuchida, Shin Nakagawa, Takeshi Inoue, Ichiro Kusumi
    Journal of Affective Disorders 0165-0327 2022/10
  • Yutaka Fujii, Satoshi Asakura, Nguyen Tan Dat, Keisuke Takanobu, Shinya Watanabe, Kuniyoshi Toyoshima, Nobuyuki Mitsui, Atsuhito Toyomaki, Naoki Hashimoto, Yuki Kako, Ichiro Kusumi
    Asian journal of psychiatry 75 103215 - 103215 2022/09
  • Yuji Yamada, Ryo Okubo, Hisateru Tachimori, Takashi Uchino, Ryotaro Kubota, Hiroki Okano, Shuhei Ishikawa, Toru Horinouchi, Keisuke Takanobu, Ryo Sawagashira, Yumi Hasegawa, Yohei Sasaki, Motohiro Nishiuchi, Takahiro Kawashima, Yui Tomo, Naoki Hashimoto, Satoru Ikezawa, Takahiro Nemoto, Norio Watanabe, Tomiki Sumiyoshi
    Frontiers in Psychology 13 2022/08/03 
    Background Social cognitive impairments adversely affect social functioning (e.g., employment status) in patients with schizophrenia. Although pharmacological interventions have been suggested to provide some benefits on social cognition, little information is available on the comparative efficacy of pharmacotherapy. Thus, the aim of this planned systematic review and network meta-analysis is to perform a quantitative comparison of the effects of various psychotropic drugs, including supplements, on social cognition disturbances of schizophrenia. Methods The literature search will be carried out using the PubMed, Embase, Cochrane Central Register of Controlled Trials, PsycINFO, ClinicalTrials.gov, and International Clinical Trials Registry Platform databases from inception onward. Randomized controlled trials that examined the efficacy of drugs in social cognitive disturbances will be included, based on the most recent studies and the broader literature than previously searched. This protocol defines a priori the methods that will be used for study selection, data collection, quality assessment, and statistical syntheses. Discussion The findings this work are expected to help promote the development of better therapeutics of social cognitive impairments in schizophrenia and related psychiatric conditions. Systematic Review Registration [www.crd.york.ac.uk/prospero], identifier [CRD42021293224].
  • Chika Sumiyoshi, Kazutaka Ohi, Haruo Fujino, Hidenaga Yamamori, Michiko Fujimoto, Yuka Yasuda, Yota Uno, Junichi Takahashi, Kentaro Morita, Asuka Katsuki, Maeri Yamamoto, Yuko Okahisa, Ayumi Sata, Eiichi Katsumoto, Michihiko Koeda, Yoji Hirano, Masahito Nakataki, Junya Matsumoto, Kenichiro Miura, Naoki Hashimoto, Manabu Makinodan, Tsutomu Takahashi, Kiyotaka Nemoto, Toshifumi Kishimoto, Michio Suzuki, Tomiki Sumiyoshi, Ryota Hashimoto
    BJPsych Open 8 (4) e98  2022/07 
    Background Cognitive impairment is common in people with mental disorders, leading to transdiagnostic classification based on cognitive characteristics. However, few studies have used this approach for intellectual abilities and functional outcomes. Aims The present study aimed to classify people with mental disorders based on intellectual abilities and functional outcomes in a data-driven manner. Method Seven hundred and forty-nine patients diagnosed with schizophrenia, bipolar disorder, major depression disorder or autism spectrum disorder and 1030 healthy control subjects were recruited from facilities in various regions of Japan. Two independent k-means cluster analyses were performed. First, intelligence variables (current estimated IQ, premorbid IQ, and IQ discrepancy) were included. Second, number of work hours per week was included instead of premorbid IQ. Results Four clusters were identified in the two analyses. These clusters were specifically characterised in terms of IQ discrepancy in the first cluster analysis, whereas the work variable was the most salient feature in the second cluster analysis. Distributions of clinical diagnoses in the two cluster analyses showed that all diagnoses were unevenly represented across the clusters. Conclusions Intellectual abilities and work outcomes are effective classifiers in transdiagnostic approaches. The results of our study also suggest the importance of diagnosis-specific strategies to support functional recovery in people with mental disorders.
  • Takashi Uchino, Ryo Okubo, Youji Takubo, Akiko Aoki, Izumi Wada, Naoki Hashimoto, Satoru Ikezawa, Takahiro Nemoto
    Psychiatry and clinical neurosciences 76 (9) 429 - 436 2022/06/29 
    AIM: Social cognition impacts social functioning in schizophrenia; however, little is known about how patients with schizophrenia themselves perceive social cognition. This study, using an internet survey, aimed to investigate their knowledge of social cognition, clinical experiences related to social cognition, awareness of social cognition's role in one's social life, and the relationships between subjective difficulties with social cognition and social functioning. METHODS: Data from 232 outpatients with schizophrenia (SZ) and 494 healthy controls (HC) were obtained through an internet survey and were weighted according to the demographics of the national population. A newly developed survey questionnaire on knowledge, experience, and awareness of social cognition was administered. Subjective difficulties were evaluated using the Self-Assessment of Social Cognition Impairments and the Observable Social Cognition Rating Scale. RESULTS: Less than a quarter of both groups were familiar with the term or concept of social cognition. Less than 5% of both groups had experienced being assessed or treated for social cognition. More than half of both groups were aware of the relationship between social cognition and social functioning. The SZ group had higher levels of subjective difficulties than the HC group across all social cognitive domains. The attributional bias domain of subjective difficulties was negatively associated with social functioning. CONCLUSION: Patients with schizophrenia had substantial subjective difficulties in social cognition, which they perceived as being related to social functioning. However, their knowledge of social cognition was limited, and the assessment and treatment might not be widespread in regular clinical practice.
  • 多施設共同研究による統合失調症・双極性障害・うつ病・自閉スペクトラム症の疾患横断的大脳皮質構造画像解析
    松本 純弥, 福永 雅喜, 三浦 健一郎, 根本 清貴, 岡田 直大, 橋本 直樹, 森田 健太郎, 越山 太輔, 大井 一高, 高橋 努, 肥田 道彦, 山森 英長, 藤本 美智子, 安田 由華, 長谷川 尚美, 成田 尚, 横山 仁史, 三嶋 亮, 河島 孝彦, 小林 祐子, 笹林 大樹, 原田 健一郎, 山本 真江里, 平野 羊嗣, 板橋 貴史, 中瀧 理仁, 橋本 龍一郎, タ・キンキン, 小池 進介, 松原 敏郎, 岡田 剛, 吉村 玲児, 阿部 修, 鬼塚 俊明, 渡邊 嘉之, 松尾 幸治, 山末 英典, 岡本 泰昌, 鈴木 道雄, 尾崎 紀夫, 笠井 清登, 橋本 亮太
    国立精神・神経医療研究センター精神保健研究所年報 (国研)国立精神・神経医療研究センター精神保健研究所 (35) 202 - 202 2022/06
  • Yumi Wakatsuki, Yukiko Ogura, Naoki Hashimoto, Atsuhito Toyomaki, Tamaki Miyamoto, Shin Nakagawa, Takeshi Inoue, Ichiro Kusumi
    Psychiatry and clinical neurosciences 76 (8) 393 - 400 2022/05/24 
    BACKGROUND: Differentiating between bipolar disorder (BD) and major depressive disorder (MDD) during the depressive episode is an important clinical challenge. Reward system abnormalities have received much attention as one of the biological underpinnings of BD and MDD, but few studies have directly compared these abnormalities in remitted and depressed states. METHODS: This was a functional MRI study using the Monetary Incentive Delay task in 65 patients (BD [n=33], MDD [n=32]) and 33 healthy controls (HC). Regions of interest (ROI) analysis with 21 ROIs related to reward anticipation and 17 ROIs related to gain outcome were implemented, as well as whole-brain analysis. The difference in the dimensional effect of depression on brain activation was also examined. RESULTS: Relative to the HC group, BD patients showed significantly decreased activation during reward anticipation in the anterior cingulate cortex, anterior insula (AI), and putamen, and MDD patients showed significantly decreased activation in the AI and brainstem. The dimensional effect of depression severity showed a trend-level difference between BD and MDD in the right brainstem and left AI. CONCLUSIONS: The current study showed a possible differential effect of depression on the reward system between MDD and BD. Further studies on reward systems might offer reliable markers to distinguish between MDD and BD patients in the depressive phase. This article is protected by copyright. All rights reserved.
  • Hisashi Yamada, Mikuni Motoyama, Naomi Hasegawa, Kenichiro Miura, Junya Matsumoto, Kazutaka Ohi, Norio Yasui-Furukori, Shusuke Numata, Masahiro Takeshima, Nobuhiro Sugiyama, Tatsuya Nagasawa, Chika Kubota, Kiyokazu Atake, Takashi Tsuboi, Kayo Ichihashi, Naoki Hashimoto, Takahiko Inagaki, Yoshikazu Takaesu, Jun-Ichi Iga, Hikaru Hori, Toshiaki Onitsuka, Hiroshi Komatsu, Akitoyo Hishimoto, Kentaro Fukumoto, Michiko Fujimoto, Toshinori Nakamura, Kiyotaka Nemoto, Ryuji Furihata, Satoshi Yamamura, Hirotaka Yamagata, Kazuyoshi Ogasawara, Eiichi Katsumoto, Atsunobu Murata, Hitoshi Iida, Shinichiro Ochi, Manabu Makinodan, Mikio Kido, Taishiro Kishimoto, Yuka Yasuda, Masahide Usami, Taro Suwa, Ken Inada, Koichiro Watanabe, Ryota Hashimoto
    BJPsych open 8 (3) e83  2022/04/21 
    BACKGROUND: Clinical practice guidelines for schizophrenia and major depressive disorder have been published. However, these have not had sufficient penetration in clinical settings. We developed the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project as a dissemination and education programme for psychiatrists. AIMS: The aim of this study is to assess the effectiveness of the EGUIDE project on the subjective clinical behaviour of psychiatrists in accordance with clinical practice guidelines before and 1 and 2 years after participation in the programmes. METHOD: A total of 607 psychiatrists participated in this study during October 2016 and March 2019. They attended both 1-day educational programmes based on the clinical practice guidelines for schizophrenia and major depressive disorder, and answered web questionnaires about their clinical behaviours before and 1 and 2 years after attending the programmes. We evaluated the changes in clinical behaviours in accordance with the clinical practice guidelines between before and 2 years after the programme. RESULTS: All of the scores for clinical behaviours in accordance with clinical practice guidelines were significantly improved after 1 and 2 years compared with before attending the programmes. There were no significant changes in any of the scores between 1 and 2 years after attending. CONCLUSIONS: All clinical behaviours in accordance with clinical practice guidelines improved after attending the EGUIDE programme, and were maintained for at least 2 years. The EGUIDE project could contribute to improved guideline-based clinical behaviour among psychiatrists.
  • Ryo Sawagashira, Ryodai Yamamura, Ryo Okubo, Naoki Hashimoto, Shuhei Ishikawa, Yoichi M Ito, Norihiro Sato, Ichiro Kusumi
    The Journal of clinical psychiatry 83 (3) 2022/03/30 
    Objective: The risk of diabetes development has been reported to differ among second-generation antipsychotics (SGAs). However, few studies have focused on the subthreshold change in glycated hemoglobin (HbA1c). Therefore, this study examined the subthreshold change in HbA1c and change in body mass index (BMI) 3 months after patients initiated one of 6 SGAs widely prescribed in Japan. Methods: This is a prospective cohort study of patients followed up based on the Japanese blood glucose monitoring guidelines for patients with schizophrenia. We collected eligible patients' demographic data, medication history, blood tests, and weight measurements both at baseline and 3 months after recruitment, between April 2013 and March 2015. In the 378 patients with schizophrenia, schizoaffective disorder, and bipolar disorder based on ICD-10, we compared the subthreshold change in HbA1c and the change in BMI 3 months after antipsychotic initiation by using multivariate regression analysis. Results: The subthreshold change in HbA1c 3 months after initiating blonanserin was significantly lower compared with olanzapine (B = -0.17, 95% CI = -0.31 to -0.04). In addition, the change in BMI 3 months after initiating blonanserin and aripiprazole was significantly lower compared with olanzapine (B = -0.93, 95% CI = -1.74 to -0.12; B = -0.71, 95% CI = -1.30 to -0.12, respectively). Conclusions: This is the first study to clarify the differences in the subthreshold change in HbA1c among SGAs. Our results suggest that blonanserin is likely to be a favorable treatment for patients with high risk of diabetes. Trial Registration: UMIN Clinical Trial Registry identifier: UMIN000009868.
  • Kazuyoshi Ogasawara, Shusuke Numata, Naomi Hasegawa, Masahito Nakataki, Manabu Makinodan, Kazutaka Ohi, Masahiro Takeshima, Takashi Tsuboi, Naoki Hashimoto, Toshiaki Onitsuka, Hiroyuki Muraoka, Hikaru Hori, Kayo Ichihashi, Takahiko Inagaki, Norio Yasui-Furukori, Akitoyo Hishimoto, Nobuhiro Sugiyama, Kentaro Fukumoto, Tatsuya Nagasawa, Junya Matsumoto, Yoshikazu Takaesu, Ryuji Furihata, Kiyotaka Nemoto, Toshinori Nakamura, Masahide Usami, Kenichiro Miura, Michiko Fujimoto, Hiromi Tagata, Hisashi Yamada, Hiroshi Komatsu, Shinichiro Ochi, Kiyokazu Atake, Eiichi Katsumoto, Mikio Kido, Taishiro Kishimoto, Taro Suwa, Satoshi Yamamura, Jun-Ichi Iga, Hitoshi Iida, Ken Inada, Koichiro Watanabe, Ryota Hashimoto
    Neuropsychopharmacology reports 42 (2) 221 - 225 2022/03/10 
    The Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE) project, which is a nationwide dissemination and implementation program for clinical practice guidelines (CPGs) in the field of psychiatry, is currently ongoing. In the current study, a subjective assessment of the participants in the EGUIDE programs was assessed using a questionnaire. Then, the relationships between the subjective assessment, the characteristics of the participants, and the clinical knowledge of the CPGs were evaluated. More than 90% of the participants gave a high rating for the components of content, recommendation, knowledge, skill, and adherence, but not for the component of confidence. A positive correlation was found between years of professional experience and the score of confidence. These results suggest that it may be necessary to apply the knowledge and skills of CPGs obtained in the education programs into practice to increase confidence in the proper use of psychiatric therapies based on CPGs.
  • Shuhei Ishikawa, Ryodai Yamamura, Naoki Hashimoto, Ryo Okubo, Ryo Sawagashira, Yoichi M Ito, Norihiro Sato, Ichiro Kusumi
    Progress in neuro-psychopharmacology & biological psychiatry 113 110453 - 110453 2022/03/08 
    There have been concerns that antipsychotics increase the incidence of hyperglycemic progression. Many factors have been suggested to contribute to the risk of antipsychotic-induced hyperglycemic progression, including the type, daily dose, and number of antipsychotics; however, few studies have examined these relationships. This study aimed to examine the affect of antipsychotic treatment-associated factors on hyperglycemic progression, after adjustment for the affect of background factors suggested to be associated with hyperglycemic progression. This was a nationwide, multicenter, prospective cohort study examining the incidence of hyperglycemic progression during a 12 mo period following the initiation of newly prescribed antipsychotic medication. Demographic data, medication history, and blood test values were collected from 631 study participants with normal blood glucose levels at baseline for 12 mo. The primary endpoint (incidence of hyperglycemic progression) was defined as progression from normal to prediabetic or probable diabetic status, and was evaluated based on the Japanese monitoring guidance in patients with schizophrenia. To further examine the affect of antipsychotics on glucose metabolism over time, we examined changes in HbA1c levels 3, 6, and 12 mo after the initiation of treatment with each antipsychotic. We found that treatment with zotepine and clozapine was associated with a significantly high incidence of hyperglycemic progression. Furthermore, changes in HbA1c levels 6 mo after the initiation of zotepine treatment were significantly higher than those following blonanserin and haloperidol treatments. In contrast, there was no significant difference in the change in total cholesterol, triglycerides, HDL cholesterol, and BMI during the same period. Moreover, the "daily dose" and "number" of antipsychotics did not show an association with the incidence of hyperglycemic progression. However, in a post hoc analysis in which the antipsychotics were divided into two groups according to the strength of blockade of H1, M1, M3, and 5-HT2C receptors, the incidence of hyperglycemic progression was higher in the medium- and high-daily dose groups than in the low-daily dose group in the antipsychotic group with strong blockade of these receptors. Our study indicated that the type of antipsychotic had a greater affect on the incidence of hyperglycemic progression than the daily dose of antipsychotics or their number. Among these, zotepine was most likely to increase the incidence of hyperglycemic progression, suggesting the need for caution when these antipsychotics are prescribed.
  • Norio Yasui-Furukori, Hiroyuki Muraoka, Naomi Hasegawa, Shinichiro Ochi, Shusuke Numata, Hikaru Hori, Akitoyo Hishimoto, Toshiaki Onitsuka, Kazutaka Ohi, Naoki Hashimoto, Tatsuya Nagasawa, Yoshikazu Takaesu, Takahiko Inagaki, Hiromi Tagata, Takashi Tsuboi, Chika Kubota, Ryuji Furihata, Jun-Ichi Iga, Hitoshi Iida, Kenichiro Miura, Junya Matsumoto, Hisashi Yamada, Koichiro Watanabe, Ken Inada, Kazutaka Shimoda, Ryota Hashimoto
    Neuropsychopharmacology reports 42 (1) 3 - 9 2022/03 
    BACKGROUND: The decision to initiate clozapine treatment should be made on an individual basis and may be closely related to the early detection of treatment-resistant schizophrenia (TRS), although there is evidence that the early use of clozapine results in a better response to treatment. Therefore, we investigated the relationship between the examination rate of TRS and the prescription rate of clozapine. METHODS: After attending a 1-day educational program on schizophrenia based on the "Guidelines for the Pharmacological Treatment of Schizophrenia," we asked the participating facilities to submit records of whether or not TRS was evaluated for each patient. We calculated the clozapine prescription rate from the schizophrenic patients prescribed clozapine and all of the schizophrenic patients. Forty-nine facilities in 2017 were included in the study. RESULTS: There were dichotomous distributions in the examination rate of TRS and a non-normal distribution in the prescription rate of clozapine. There was a significant correlation between the prescription rate of clozapine and the examination rate of TRS (r s  = 0.531, P = 1.032 × 10-4 ). A significant difference was found in the prescription rate of clozapine between the three groups of facilities according to the examination rate of TRS. CONCLUSION: As a preliminary problem for the use of clozapine, in Japan, the examination rate of TRS varies, and there are many facilities that typically do not consider the possibility of TRS; this trend leads to a low rate of clozapine use. Clearly, further clinician training is needed for the early detection and appropriate management of TRS that includes an explanation of TRS and how to introduce clozapine therapy to patients and their families.
  • Kayo Ichihashi, Yoshitaka Kyou, Naomi Hasegawa, Norio Yasui-Furukori, Yoshihito Shimizu, Hikaru Hori, Naoki Hashimoto, Kenta Ide, Yayoi Imamura, Hisashi Yamada, Shinichiro Ochi, Jun-Ichi Iga, Yoshikazu Takaesu, Kazutaka Ohi, Takashi Tsuboi, Hitoshi Iida, Hirotaka Yamagata, Akitoyo Hishimoto, Tadasu Horai, Masahide Usami, Manabu Makinodan, Tatsuya Nagasawa, Hiroshi Komatsu, Mikio Kido, Hiroyuki Muraoka, Kiyokazu Atake, Masahiro Takeshima, Chika Kubota, Takahiko Inagaki, Shinichiro Tamai, Taishiro Kishimoto, Ryuji Furihata, Junya Matsumoto, Kenichiro Miura, Ken Inada, Koichiro Watanabe, Kiyoto Kasai, Ryota Hashimoto
    Asian journal of psychiatry 69 103007 - 103007 2022/03 
    BACKGROUND: Although several guidelines indicate that daily pharmacotherapy is an important part of the treatment of schizophrenia and major depressive disorder, there are few reports regarding pro re nata (PRN) prescriptions. The purpose of this study is to clarify the characteristics of patients receiving psychotropic PRN prescription for the treatment of schizophrenia and major depressive disorder. METHOD: We used data from 'the effectiveness of guideline for dissemination and education in psychiatric treatment' (EGUIDE) project to evaluate the presence or absence of psychotropic PRN prescription at the time of discharge, the age and sex of patients receiving PRN prescription for each diagnosis, and the association between PRN prescription and regular daily psychotropics. RESULTS: The psychotropic PRN prescription ratio was 29.9% among 2617 patients with schizophrenia and 31.1% among 1248 patients with major depressive disorder at discharge. In schizophrenia, the psychotropic PRN prescription ratio was 21.6% for patients aged 65 years or older, which was lower than that of all other age groups. In major depressive disorder, the psychotropic PRN prescription ratio was 34.2% for female patients, which was significantly higher than that for male patients (25.5%). In schizophrenia, there was an association between psychotropic PRN prescription and regular use of multiple psychotropic medications. CONCLUSIONS: Psychotropic PRN prescription was less common in elderly patients with schizophrenia and more common in female patients with major depressive disorder. In schizophrenia, psychotropic PRN prescription led to polypharmacy of psychotropics. Further studies are needed to accumulate evidence and to provide education on appropriate PRN prescriptions.
  • Hiroaki Kubo, Hiromi Urata, Motohiro Sakai, Shunsuke Nonaka, Junji Kishimoto, Kazuhiko Saito, Masaru Tateno, Keiji Kobara, Daisuke Fujisawa, Naoki Hashimoto, Yuriko Suzuki, Yoko Honda, Tomohiro Nakao, Kotaro Otsuka, Shigenobu Kanba, Toshihide Kuroki, Takahiro A Kato
    Frontiers in psychiatry 13 1029653 - 1029653 2022 
    BACKGROUNDS: Hikikomori, pathological social withdrawal, is becoming a crucial mental health issue in Japan and worldwide. We have developed a 3-day family intervention program for hikikomori sufferers based on Mental Health First Aid (MHFA) and Community Reinforcement and Family Training (CRAFT). This study aims to confirm the effectiveness of the 3-day program by a randomized controlled trial. METHODS: This study was registered on the UMIN Clinical Trials Registry (UMIN000037289). Fifteen parents were assigned to the treat as usual (TAU) group (TAU only; Age Mean, 65.6; SD, 7.8), and 14 to the Program group (program + TAU; Age Mean, 67.9; SD, 8.6). This study was discontinued due to the COVID-19 pandemic; the recruitment rate was 36.3% of our target sample size of 80. RESULTS: Perceived skills improved temporally and stigma temporally worsened in the TAU group. Confidence decreased and attitude showed no change in both groups. Aggressive behaviors of hikikomori sufferers were significantly worsened in the Program group; however, no serious domestic violence was reported. In the TAU group, Avoidance and irregular life patterns were improved. Activity levels were worsened in both groups. Two participants (16.7%) in the Program group and one participant (7.7%) in the TAU group reported actual behavioral changes (e.g., utilizing support). CONCLUSION: We could not draw general conclusions on the effectiveness of the program due to the study discontinuation. Nevertheless, this study indicates the necessity for revision of the program to improve family members' confidence in engaging with hikikomori sufferers, with safer approaching by families.
  • Hikaru Hori, Norio Yasui-Furukori, Naomi Hasegawa, Jun-Ichi Iga, Shinichiro Ochi, Kayo Ichihashi, Ryuji Furihata, Yoshitaka Kyo, Yoshikazu Takaesu, Takashi Tsuboi, Fumitoshi Kodaka, Toshiaki Onitsuka, Tsuyoshi Okada, Atsunobu Murata, Hiroko Kashiwagi, Hitoshi Iida, Naoki Hashimoto, Kazutaka Ohi, Hisashi Yamada, Kazuyoshi Ogasawara, Yuka Yasuda, Hiroyuki Muraoka, Masahide Usami, Shusuke Numata, Masahiro Takeshima, Hirotaka Yamagata, Tatsuya Nagasawa, Hiromi Tagata, Manabu Makinodan, Mikio Kido, Eiichi Katsumoto, Hiroshi Komatsu, Junya Matsumoto, Chika Kubota, Kenichiro Miura, Akitoyo Hishimoto, Koichiro Watanabe, Ken Inada, Hiroaki Kawasaki, Ryota Hashimoto
    Frontiers in psychiatry 13 823826 - 823826 2022 
    In several clinical guidelines for schizophrenia, long-term use of anticholinergic drugs is not recommended. We investigated the characteristics of the use of anticholinergics in patients with schizophrenia by considering psychotropic prescription patterns and differences among hospitals. A cross-sectional, retrospective prescription survey at the time of discharge was conducted on 2027 patients with schizophrenia from 69 Japanese hospitals. We examined the relations among psychotropic drug prescriptions regarding anticholinergic prescription. We divided the hospitals into three groups-low rate group (LG), medium rate group (MG), and high rate group (HG)-according to their anticholinergic prescription rates, and analyzed the relationship between anticholinergic prescription rates and antipsychotic prescription. Anticholinergic drugs were prescribed to 618 patients (30.5%), and the prescription rates were significantly higher for high antipsychotic doses, antipsychotic polypharmacy, and first-generation antipsychotics (FGAs) use. The anticholinergic prescription rate varied considerably among hospitals, ranging from 0 to 66.7%, and it was significantly higher in patients with antipsychotic monotherapy, antipsychotic polypharmacy, and normal and high doses of antipsychotics in HG than in those LG and MG. The anticholinergics prescription rate in patients with second-generation antipsychotic monotherapy in HG was also significantly higher than in those LG and MG; however, the difference was no longer significant in patients with FGA monotherapy. Conclusively, in addition to high antipsychotic doses, antipsychotic polypharmacy, and FGA use, hospital characteristics influence the prescribing of anticholinergic drugs.
  • Kazuyori Yagyu, Atsuhito Toyomaki, Naoki Hashimoto, Hideaki Shiraishi, Ichiro Kusumi, Harumitsu Murohashi
    Frontiers in psychology 13 904995 - 904995 2022 
    Background: Difficulty in distinguishing between self-generated actions and those generated by others is a core feature of schizophrenia. This is thought to be underpinned by the failure of corollary discharge. However, few studies have investigated these events using somatosensory evoked potentials (SEPs) and somatosensory evoked magnetic fields (SEFs). Methods: The study included 15 right-handed patients with schizophrenia and 16 healthy controls. SEP and SEF were elicited by electrical stimuli to the left median nerve at intervals of 1-3 s. In the external condition, stimuli were externally induced by a machine. In the self-condition, stimuli were induced by tapping the participants' own right index finger. Peak amplitude at C4' in SEP and root mean square in 10 channels on the right primary somatosensory area in SEF were analyzed. Results: Although there was a significant main effect of condition at N20m, and a significant main effect of condition and group at P30m, no significant interactions of condition and group were found in either N20m or P30m. The post-hoc Wilcoxon signed-rank test revealed that the peak value of P30m in the external condition was significantly higher than that in the self-condition in the healthy control group only. In addition, there was a significant positive correlation between the peak value of P30m in the self-condition and a positive symptom score. Conclusion: In the current study, we did not find abnormalities of corollary discharge in primary sensory areas in patients with schizophrenia. Further investigations with more cases may reveal the possibility of corollary discharge disturbance in the primary sensory cortex.
  • Toshiaki Onitsuka, Yoji Hirano, Kiyotaka Nemoto, Naoki Hashimoto, Itaru Kushima, Daisuke Koshiyama, Michihiko Koeda, Tsutomu Takahashi, Yoshihiro Noda, Junya Matsumoto, Kenichiro Miura, Takanobu Nakazawa, Takatoshi Hikida, Kiyoto Kasai, Norio Ozaki, Ryota Hashimoto
    Psychiatry and clinical neurosciences 76 (1) 1 - 14 2022/01 
    The underlying pathologies of psychiatric disorders, which cause substantial personal and social losses, remain unknown, and their elucidation is an urgent issue. To clarify the core pathological mechanisms underlying psychiatric disorders, in addition to laboratory-based research that incorporates the latest findings, it is necessary to conduct large-sample-size research and verify reproducibility. For this purpose, it is critical to conduct multicenter collaborative research across various fields, such as psychiatry, neuroscience, molecular biology, genomics, neuroimaging, cognitive science, neurophysiology, psychology, and pharmacology. Moreover, collaborative research plays an important role in the development of young researchers. In this respect, the Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA) consortium and Cognitive Genetics Collaborative Research Organization (COCORO) have played important roles. In this review, we first overview the importance of multicenter collaborative research and our target psychiatric disorders. Then, we introduce research findings on the pathophysiology of psychiatric disorders from neurocognitive, neurophysiological, neuroimaging, genetic, and basic neuroscience perspectives, focusing mainly on the findings obtained by COCORO. It is our hope that multicenter collaborative research will contribute to the elucidation of the pathological basis of psychiatric disorders.
  • Ryuji Furihata, Rei Otsuki, Naomi Hasegawa, Takashi Tsuboi, Shusuke Numata, Norio Yasui-Furukori, Hiroko Kashiwagi, Hikaru Hori, Shinichiro Ochi, Hiroyuki Muraoka, Toshiaki Onitsuka, Hiroshi Komatsu, Masahiro Takeshima, Akitoyo Hishimoto, Tatsuya Nagasawa, Yoshikazu Takaesu, Toshinori Nakamura, Takeshi Asami, Kenichiro Miura, Junya Matsumoto, Kazutaka Ohi, Yuka Yasuda, Hitoshi Iida, Kazuyoshi Ogasawara, Naoki Hashimoto, Kayo Ichihashi, Hisashi Yamada, Koichiro Watanabe, Ken Inada, Ryota Hashimoto
    Sleep medicine 89 23 - 30 2022/01 
    STUDY OBJECTIVES: To investigate the proportion of inpatients with schizophrenia and major depressive disorder prescribed hypnotic medication, and the association between such medication and the use of other antipsychotic agents. METHODS: This was a nationwide cross-sectional study performed as part of the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment' (EGUIDE) project. Data from 2146 inpatients with schizophrenia and 1031 inpatients with major depressive disorder were analyzed. All types and dosages of psychotropic drugs were recorded and the data at the time of discharge were analyzed. Associations between the use of hypnotic medication and other antipsychotic agents were evaluated using multivariate logistic regression analyses. RESULTS: The proportions of schizophrenia patients who were prescribed any and two or more hypnotic agents were 55.7% and 17.6%, respectively, and the corresponding proportions for patients with major depressive disorder were 63.6% and 22.6%, respectively. In schizophrenia patients, multivariate logistic regression analyses showed that two or more antipsychotics, anticholinergic drugs, anxiolytics, and mood stabilizers/antiepileptic drugs were positively associated with the use of any hypnotic agent. In patients with major depressive disorder, multivariate logistic regression analyses revealed that two or more antidepressants, two or more antipsychotics, anxiolytics, and mood stabilizers/antiepileptic drugs were positively associated with the use of any hypnotic agent. CONCLUSIONS: Prescription of hypnotic agents was found to be highly frequent among inpatients with psychiatric disorders. Prescription of two or more main antipsychotic agents was commonly associated with the use of hypnotic medication for both schizophrenia and major depressive disorder.
  • Hiroyoshi Takeuchi, Yoshiteru Takekita, Hikaru Hori, Kazuto Oya, Itaru Miura, Naoki Hashimoto, Norio Yasui-Furukori
    Human psychopharmacology 36 (6) e2804  2021/11 
    OBJECTIVE: There are only a few treatment algorithms for first-episode schizophrenia. Moreover, all the algorithms apply to acute treatment, but not maintenance treatment. Therefore, we aimed to develop acute and maintenance treatment algorithms for first-episode schizophrenia. METHODS: The algorithm committee of the Japanese Society of Clinical Neuropsychopharmacology developed pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia. RESULTS: The acute treatment algorithm focuses on drug-naïve patients with first-episode schizophrenia who are not old or very agitated and recommends first-line treatment with aripiprazole, second- or third-line treatment with risperidone/paliperidone or olanzapine, and fourth-line treatment with clozapine. Long-acting injection of the current antipsychotic agent can be used for poor medication adherence or based on patient preference. The agitation treatment algorithm recommends first-line treatment with lorazepam and second- or third-line treatment with quetiapine or levomepromazine and clearly instructs that the medication used for agitation should be reduced and then discontinued after remission of agitation. The maintenance treatment algorithm recommends the gradual reduction of antipsychotics to the minimum effective dose after remission of positive symptoms. CONCLUSIONS: We hope that our unique algorithms will be used broadly and will contribute to minimizing patients' burden related to antipsychotic treatment.
  • 橋本 直樹, 豊巻 敦人, 久住 一郎
    Precision Medicine (株)北隆館 4 (11) 1081 - 1084 2434-3625 2021/10 
    統合失調症患者の陰性症状は、長期予後、生活の質の低下に大きく影響する一方で有効な治療法に乏しく、病態の理解と治療法の開発が求められる分野である。近年の研究では陰性症状は「動機づけ」と関連する因子と、「感情表出」と関連する因子の2因子構造であることが明らかになってきている。本稿ではこのうちの動機づけと関連する因子について、統合失調症患者における行動および画像研究の結果を概説する。(著者抄録)
  • Ryodai Yamamura, Ryo Okubo, Noriko Katsumata, Toshitaka Odamaki, Naoki Hashimoto, Ichiro Kusumi, Jinzhong Xiao, Yutaka J. Matsuoka
    Journal of Personalized Medicine 11 (10) 987 - 987 2021/09/30 
    A recent meta-analysis found that probiotics have moderate-to-large beneficial effects on depressive symptoms in patients with psychiatric disorders. However, it remains unclear how the baseline gut microbiota before probiotic administration influences the host’s response to probiotics. Therefore, we aimed to determine whether the predicted functional profile of the gut microbiota influences the effectiveness of probiotic treatment in patients with schizophrenia. A total of 29 patients with schizophrenia consumed Bifidobacterium breve A-1 (synonym B. breve MCC1274) for 4 weeks. We considered patients who showed a 25% or more reduction in the Hospital Anxiety and Depression Scale total score at 4 weeks from baseline to be “responders” and those who did not to be “non-responders”. We predicted the gut microbial functional genes based on 16S rRNA gene sequences and applied the linear discriminant analysis effect size method to determine the gut microbial functional genes most likely to explain the differences between responders and non-responders at baseline. The results showed that lipid and energy metabolism was elevated at baseline in responders (n = 12) compared to non-responders (n = 17). These findings highlight the importance of assessing the gut microbial functional genes at baseline before probiotic therapy initiation in patients with psychiatric disorders.
  • Naoki Hashimoto, Norio Yasui-Furukori, Naomi Hasegawa, Shuhei Ishikawa, Shusuke Numata, Hikaru Hori, Hitoshi Iida, Kayo Ichihashi, Ryuji Furihata, Atsunobu Murata, Takashi Tsuboi, Masahiro Takeshima, Yoshitaka Kyou, Hiroshi Komatsu, Chika Kubota, Shinichiro Ochi, Yoshikazu Takaesu, Masahide Usami, Tatsuya Nagasawa, Akitoyo Hishimoto, Kenichiro Miura, Junya Matsumoto, Kazutaka Ohi, Hisashi Yamada, Ken Inada, Koichiro Watanabe, Kazutaka Shimoda, Ryota Hashimoto
    Asian journal of psychiatry 63 102744 - 102744 2021/09 
    BACKGROUND: Monopharmacy with antipsychotics and antidepressants is the first-line treatment for schizophrenia and major depressive disorder (MDD) in most clinical guidelines, while polypharmacy with psychotropic agents in the treatment of schizophrenia is common in clinical practice. There are no detailed data on the prescription patterns for inpatients with mental illness with reliable diagnoses made by treating psychiatrists. METHODS: We gathered prescription data at discharge from 2177 patients with schizophrenia and 1238 patients with MDD from October 2016 to March 2018. RESULTS: The patients with schizophrenia aged between 60 and 79 were prescribed lower doses of antipsychotics and hypnotics/anxiolytics than those aged between 40 and 59. There were significant differences between the prescription rate of antipsychotics in the patients with schizophrenia and that of antidepressants in the patients with MDD. The frequency of concomitant drugs such as anti-Parkinson drugs, anxiolytics/hypnotics and mood stabilizers in the subjects with schizophrenia prescribed antipsychotic polypharmacy was significantly higher than that with monotherapy. For the patients with schizophrenia, olanzapine, risperidone, aripiprazole, quetiapine, and blonanserin were the five most prescribed antipsychotics. For the patients with MDD, mirtazapine, duloxetine, escitalopram, trazodone and sertraline were the five most prescribed antidepressants. CONCLUSIONS: Our results showed the use of high doses of antipsychotics, high percentages of antipsychotic polypharmacy and concurrent use of hypnotics/anxiolytics in patients with schizophrenia. Notably, these data were collected before intensive instruction regarding the guidelines; therefore, we need to assess the change in the prescription pattern post guideline instruction.
  • Ryotaro Kubota, Ryo Okubo, Hisashi Akiyama, Hiroki Okano, Satoru Ikezawa, Akane Miyazaki, Atsuhito Toyomaki, Yohei Sasaki, Yuji Yamada, Takashi Uchino, Takahiro Nemoto, Tomiki Sumiyoshi, Naoki Yoshimura, Naoki Hashimoto
    Journal of Personalized Medicine 11 (7) 667 - 667 2021/07/16 
    In schizophrenia, social cognitive impairment is considered one of the greatest obstacles to social participation. Although numerous measures have been developed to assess social cognition, only a limited number of them have become available in Japan. We are therefore planning this evaluation study for social cognition measures in Japan (ESCoM) to confirm their psychometric characteristics and to promote research focused on social cognition. Participants in the cross-sectional observational study will be 140 patients with schizophrenia recruited from three Japanese facilities and 70 healthy individuals. In our primary analysis, we will calculate several psychometric indicators with a focus on whether they can independently predict social functioning. In secondary analyses, we will assess the reliability and validity of the Japanese translations of each measure and conduct an exploratory investigation of patient background, psychiatric symptoms, defeatist performance belief, and gut microbiota as determinants of social cognition. The protocol for this study is registered in UMIN-CTR, unique ID UMIN000043777.
  • うつ病患者の退院時処方の特徴 EGUIDEデータより
    古郡 規雄, 橋本 直樹, 長谷川 尚美, 沼田 周助, 堀 輝, 降籏 隆二, 飯田 仁志, 市橋 香代, 三浦 健一郎, 松本 純弥, 稲田 健, 渡邊 衡一郎, 橋本 亮太
    日本うつ病学会総会・日本認知療法・認知行動療法学会プログラム・抄録集 日本うつ病学会・日本認知療法・認知行動療法学会 18回・21回 379 - 379 2021/07
  • Hiroaki Kubo, Hiromi Urata, Motohiro Sakai, Shunsuke Nonaka, Junji Kishimoto, Kazuhiko Saito, Masaru Tateno, Keiji Kobara, Daisuke Fujisawa, Naoki Hashimoto, Yuriko Suzuki, Yoko Honda, Kotaro Otsuka, Shigenobu Kanba, Toshihide Kuroki, Takahiro A. Kato
    Japanese Psychological Research 65 (2) 190 - 199 0021-5368 2021/06/02
  • Takashi Ozaki, Atsuhito Toyomaki, Naoki Hashimoto, Ichiro Kusumi
    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology 19 (2) 313 - 322 2021/05/31 
    Objective: The effect of antipsychotic drugs on quantitative electroencephalography (EEG) has been mainly examined by the administration of a single test dose or among patients using combinations of other psychotropic drugs. We therefore investigated the effects of strict monotherapy with antipsychotic drugs on quantitative EEG among schizophrenia patients. Methods: Data from 2,364 medical reports with EEG results from psychiatric patients admitted to the Hokkaido University Hospital were used. We extracted EEG records of patients who were diagnosed with schizophrenia spectrum disorders and who were either undergoing strict antipsychotic monotherapy or were completely free of psychotropic drugs. The spectral power was compared between drug-free patients and patients using antipsychotic drugs. We also performed multiple regression analysis to evaluate the relationship between spectral power and the chlorpromazine equivalent daily dose of antipsychotics in all the patients. Results: We included 31 monotherapy and 20 drug-free patients. Compared with drug-free patients, patients receiving antipsychotic drugs demonstrated significant increases in theta, alpha and beta power. When patients taking different types of antipsychotics were compared with drug-free patients, we found no significant change in any spectrum power for the aripiprazole or blonanserin groups. Patients taking risperidone demonstrated significant increases in alpha and beta power. Patients taking clozapine and olanzapine demonstrated significant slow wave increases. Multiple regression analysis revealed that the chlorpromazine equivalent dose was positively associated with theta power. Conclusion: Use of any antipsychotic drug by patients was associated with a dose-dependent increase in theta power. However, each type of antipsychotic demonstrated different spectral power changes.
  • Hiroki Okano, Ryotaro Kubota, Ryo Okubo, Naoki Hashimoto, Satoru Ikezawa, Atsuhito Toyomaki, Akane Miyazaki, Yohei Sasaki, Yuji Yamada, Takahiro Nemoto, Masafumi Mizuno
    Journal of Personalized Medicine 11 (4) 275 - 275 2021/04/06 
    Social cognition is strongly linked to social functioning outcomes, making it a promising treatment target. Because social cognition measures tend to be sensitive to linguistic and cultural differences, existing measures should be evaluated based on their relevance for Japanese populations. We aimed to establish an expert consensus on the use of social cognition measures in Japanese populations to provide grounds for clinical use and future treatment development. We assembled a panel of experts in the fields of schizophrenia, social psychology, social neuroscience, and developmental disorders. The panel engaged in a modified Delphi process to (1) affirm expert consensus on the definition of social cognition and its constituent domains, (2) determine criteria to evaluate measures, and (3) identify measures appropriate for Japanese patients with a view toward future quantitative research. Through two online voting rounds and two online video conferences, the panel agreed upon a definition and four-domain framework for social cognition consistent with recent literature. Evaluation criteria for measures included feasibility and tolerability, reliability, clinical effectiveness, validity, and international comparability. The panel finally identified nine promising measures, including one task originally developed in Japan. In conclusion, we established an expert consensus on key discussion points in social cognition and arrived at an expert-selected set of measures. We hope that this work facilitates the use of these measures in Japanese clinical scenarios. We plan to further examine these measures in a psychometric evaluation study.
  • Naoki Hashimoto, Hiroko Takeda, Yutaka Fujii, Yuriko Suzuki, Takahiro A. Kato, Daisuke Fujisawa, Kumi Aoyama-Uehara, Kotaro Otsuka, Nobuyuki Mitsui, Satoshi Asakura, Ichiro Kusumi
    Asian Journal of Psychiatry 102661 - 102661 1876-2018 2021/04
  • Yuri Sakai, Chong Chen, Atsuhito Toyomaki, Naoki Hashimoto, Kan Kitagawa, Takao Inoue, Asumi Sato, Keisuke Makihara, Rie Kameyama, Yumi Wakatsuki, Niki Udo, Ryosuke Shirakawa, Takashi Yokota, Shin Nakagawa, Ichiro Kusumi
    Frontiers in behavioral neuroscience 15 787688 - 787688 2021 
    Due to the fact that existing pharmacological treatments for depression are not ideal, effort has been devoted to the development of complementary, alternative therapies such as physical exercise. The antidepressant effect of exercise is well documented. However, current recommendations and prescriptions of exercise may be too demanding for depressed patients, as some complain about the design of exercise programs and depression is associated with reduced motivation and capacity to exercise. Therefore, appropriately designed, patient-friendly exercise programs may prove critical for the long-term maintenance and therapeutic effects of exercise. In this pilot study, we developed an exercise program based on patients' individual level of ventilatory threshold (VT), a submaximal index of aerobic capacity measured by Cardiopulmonary Exercise Testing (CPX). Compared to traditional measures, CPX provides more trustable indices of aerobic capacity and more homogenous exercise prescriptions. The main episode of the program consisted of 15-25 min of cycling twice a week at an intensity that approached but never went higher than subjects' VT (considered low to moderate in intensity). We found that in patients diagnosed with major depressive disorder or persistent depressive disorder (n = 8), the program resulted in a significant reduction in depressive symptoms at week 8, which was maintained at week 16. Meanwhile, patients' social functioning, quality of life, and cognitive functions improved. Although we used a single arm, non-randomized design, our results suggest that even a brief, low to moderate intensity exercise program may exert therapeutic effects for depression and CPX may be a useful tool for exercise prescriptions.
  • Shuhei Ishikawa, Masaki Kobayashi, Naoki Hashimoto, Hideaki Mikami, Akihiko Tanimura, Katsuya Narumi, Ayako Furugen, Ichiro Kusumi, Ken Iseki
    The Journal of pharmacology and experimental therapeutics 375 (2) 376 - 384 2020/11 
    Clozapine-induced sialorrhea (CIS) is a common side effect of clozapine. There is no established standard treatment of CIS since the underlying mechanism remains unknown. This study aimed to elucidate the mechanisms involved in CIS. In our clinical study, a prospective observational study evaluated the association between serum and saliva concentrations of clozapine or its metabolites and Drooling Severity and Frequency Scale (DSFS) score. In our in vivo study, we first developed a new CIS animal model; subsequently, we measured salivary secretion and concentrations of clozapine or its metabolites in the animal model. In our in vitro study, we measured the calcium ion (Ca2+) response to evaluate the effect of clozapine or its metabolites on human salivary gland cell line (HSY cells) and then examined whether their effect was inhibited by atropine. In our clinical study, serum and saliva N-desmethylclozapine concentrations were significantly correlated with nocturnal DSFS score. In our in vivo study, daily single oral administration of 100 mg/kg clozapine for 7 days significantly increased salivary secretion in rats. Furthermore, N-desmethylclozapine concentrations in serum and submandibular glands of the rats were higher than clozapine concentrations. In our in vitro study, N-desmethylclozapine only elicited an increase in the intracellular Ca2+ in HSY cells. N-desmethylclozapine-induced Ca2+ responses were inhibited by atropine. These results suggest that N-desmethylclozapine is implicated in CIS by increasing nocturnal salivation via the muscarinic receptors. Moreover, our developed animal model that reflects CIS in clinical condition plays a key role as a bridge between basic and clinical research. SIGNIFICANCE STATEMENT: Clozapine-induced sialorrhea (CIS) is a severe and frequent adverse reaction, but the mechanism underlying CIS is less well understood. This paper reports that N-desmethylclozapine, a metabolite of clozapine, is implicated in CIS by increasing nocturnal salivation via the muscarinic receptors and that oral administration of clozapine at 100 mg/kg once daily for 7 days to rat is the optimum method for establishing the new animal model reflecting the clinical scenario of CIS.
  • Hitoshi Iida, Junichi Iga, Naomi Hasegawa, Yuka Yasuda, Tomoya Yamamoto, Kenichiro Miura, Junya Matsumoto, Atsunobu Murata, Kazuyoshi Ogasawara, Hisashi Yamada, Hikaru Hori, Kayo Ichihashi, Naoki Hashimoto, Kazutaka Ohi, Norio Yasui‐Furukori, Takashi Tsuboi, Toshinori Nakamura, Masahide Usami, Ryuji Furihata, Yoshikazu Takaesu, Kunihiro Iwamoto, Nobuhiro Sugiyama, Taishiro Kishimoto, Naohisa Tsujino, Hiroki Yamada, Akitoyo Hishimoto, Kiyotaka Nemoto, Kiyokazu Atake, Hiroyuki Muraoka, Eiichi Katsumoto, Satoru Oishi, Takahiko Inagaki, Fumiaki Ito, Yayoi Imamura, Mikio Kido, Tatsuya Nagasawa, Shusuke Numata, Shinichiro Ochi, Masaaki Iwata, Hidenaga Yamamori, Junichi Fujita, Toshiaki Onitsuka, Satoshi Yamamura, Manabu Makinodan, Michiko Fujimoto, Yoichiro Takayanagi, Kenji Takezawa, Hiroshi Komatsu, Kentaro Fukumoto, Shinichiro Tamai, Hirotaka Yamagata, Chika Kubota, Tadasu Horai, Ken Inada, Koichiro Watanabe, Hiroaki Kawasaki, Ryota Hashimoto
    Psychiatry and Clinical Neurosciences 1323-1316 2020/10/09
  • Niki Udo, Naoki Hashimoto, Takuya Toyonaga, Tomoyuki Isoyama, Yuka Oyanagi, Hisashi Narita, Tohru Shiga, Shin Nakagawa, Ichiro Kusumi
    Dementia and Geriatric Cognitive Disorders Extra 10 (2) 86 - 93 2020/09/09 
    Introduction: Apathy is a common neuropsychiatric symptom in patients with Alzheimer’s disease (AD). The striatal binding potential (BP) of 123I-FP-CIT (N-δ-fluoropropyl-2β-carbomethoxy-3β-[4-iodophenyl]tropane) single-photon emission computed tomography (SPECT) is correlated with the degree of apathy in patients with Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). This study aimed to determine if dopaminergic activity in the basal ganglia is associated with the development of apathy in AD. Methods: Nineteen subjects with AD were included and underwent 123I-FP-CIT-SPECT. Patients with other types of dementia as a comorbidity, those taking antidepressants, and those with overt parkinsonism were excluded. Apathy was assessed using the Apathy Evaluation Scale Informant-Japanese version (AES-I-J). SPECT images were overlaid with images in striatal regions of interest (ROIs), and the SPECT values in these regions were counted. The relationship between BP values and AES-I-J scores was investigated using Spearman’s rank correlation coefficient. Results: Significant inverse correlations were observed between BP values and AES-I-J scores in the left caudate nucleus and there was a marginally significant inverse correlation in the right caudate nucleus. Conclusion: The pathological basis of apathy might be the impairment of the dopaminergic nervous system. Further studies on more subjects with AD, healthy controls, and patients with PD and DLB are needed.
  • Naoki Hashimoto, Timothy I. Michaels, Roeland Hancock, Ichiro Kusumi, Fumiko Hoeft
    Psychiatry and Clinical Neurosciences 74 (7) 392 - 397 1323-1316 2020/07
  • Naoki Hashimoto, Katsuyoshi Takahashi, Daisuke Fujisawa, Kumi Aoyama, Atsuo Nakagawa, Naoe Okamura, Atsuhito Toyomaki, Matsuhiko Oka, Keisuke Takanobu, Ryo Okubo, Hisashi Narita, Kan Kitagawa, Niki Udo, Tamaki Maeda, Shinya Watanabe, Yuka Oyanagi, Akane Miyazaki, Koki Ito, Ichiro Kusumi
    Asian journal of psychiatry 54 102210 - 102210 2020/06/16 [Refereed][Not invited]
  • Daisuke Sawamura, Hisashi Narita, Naoki Hashimoto, Shin Nakagawa, Hiroyuki Hamaguchi, Noriyuki Fujima, Kohsuke Kudo, Hiroki Shirato, Khin K Tha
    Journal of magnetic resonance imaging : JMRI 2020/04/23 [Refereed][Not invited]
     
    BACKGROUND: Identifying structural and functional abnormalities in bipolar (BD) and major depressive disorders (MDD) is important for understanding biological processes. HYPOTHESIS: Diffusion kurtosis imaging (DKI) may be able to detect the brain's microstructural alterations in BD and MDD and any differences between the two. STUDY TYPE: Prospective. SUBJECTS: In all, 16 BD patients, 19 MDD patients, and 20 age- and gender-matched healthy volunteers. FIELD STRENGTH/SEQUENCE: DKI at 3.0T. ASSESSMENT: The major DKI indices of the brain were compared voxel-by-voxel among the three groups. Significantly different voxels were tested for correlation with clinical variables (ie, Young Mania Rating Scale [YMRS], 17-item Hamilton Depression Rating Scale [17-HDRS], Montgomery-Åsberg Depression Rating Scale, total disease duration, duration of current episode, and the number of past manic/depressive episodes). The performance of the DKI indices in identifying microstructural alterations was estimated. STATISTICAL TESTS: One-way analysis of variance (ANOVA) was used for group comparison of DKI indices. The performance of these indices in detecting microstructural alterations was determined by receiver operating characteristic (ROC) analysis. Pearson's product-moment correlation analyses were used to test the correlations of these indices with clinical variables. RESULTS: DKI revealed widespread microstructural alterations across the brain in each disorder (P < 0.05). Some were significantly different between the two disorders. Mean kurtosis (MK) in the gray matter of the right inferior parietal lobe was able to distinguish BD and MDD with an accuracy of 0.906. A strong correlation was revealed between MK in that region and YMRS in BD patients (r = -0.641, corrected P = 0.042) or 17-HDRS in MDD patients (r = -0.613, corrected P = 0.030). There were also strong correlations between a few other DKI indices and disease duration (r = -0.676 or 0.626, corrected P < 0.05). DATA CONCLUSION: DKI detected microstructural brain alterations in BD and MDD. Its indices may be useful to distinguish the two disorders or to reflect disease severity and duration. LEVEL OF EVIDENCE: 2 TECHNICAL EFFICACY STAGE: 3.
  • Daisuke Koshiyama, Masaki Fukunaga, Naohiro Okada, Kentaro Morita, Kiyotaka Nemoto, Kaori Usui, Hidenaga Yamamori, Yuka Yasuda, Michiko Fujimoto, Noriko Kudo, Hirotsugu Azechi, Yoshiyuki Watanabe, Naoki Hashimoto, Hisashi Narita, Ichiro Kusumi, Kazutaka Ohi, Takamitsu Shimada, Yuzuru Kataoka, Maeri Yamamoto, Norio Ozaki, Go Okada, Yasumasa Okamoto, Kenichiro Harada, Koji Matsuo, Hidenori Yamasue, Osamu Abe, Ryuichiro Hashimoto, Tsutomu Takahashi, Tomoki Hori, Masahito Nakataki, Toshiaki Onitsuka, Laurena Holleran, Neda Jahanshad, Theo G M van Erp, Jessica Turner, Gary Donohoe, Paul M Thompson, Kiyoto Kasai, Ryota Hashimoto
    Molecular psychiatry 25 (4) 697 - 698 2020/04 [Refereed][Not invited]
  • 精神科医療の普及と教育に対するガイドラインの効果に関する研究[Effective of GUIdeline for Dissemination and Education in psychiatric treatment(EGUIDE)プロジェクト] 北海道地区の状況
    橋本 直樹, 賀古 勇輝, 久住 一郎
    精神神経学雑誌 (公社)日本精神神経学会 122 (2) 169 - 169 0033-2658 2020/02
  • Yumi Wakatsuki, Takeshi Inoue, Naoki Hashimoto, Yota Fujimura, Jiro Masuya, Masahiko Ichiki, Hajime Tanabe, Ichiro Kusumi
    Neuropsychiatric Disease and Treatment Volume 16 1 - 10 2020/01
  • Hiroaki Kubo, Hiromi Urata, Motohiro Sakai, Shunsuke Nonaka, Kazuhiko Saito, Masaru Tateno, Keiji Kobara, Naoki Hashimoto, Daisuke Fujisawa, Yuriko Suzuki, Kotaro Otsuka, Hiroho Kamimae, Yuya Muto, Takashi Usami, Yoko Honda, Junji Kishimoto, Toshihide Kuroki, Shigenobu Kanba, Takahiro A Kato
    Heliyon 6 (1) e03011  2020/01 [Refereed][Not invited]
     
    Backgrounds: Hikikomori, a severe form of social withdrawal, is increasingly a serious mental health issue worldwide. Hikikomori is comorbid with various psychiatric conditions including depression, social anxiety and suicidal behaviors. Family support is encouraged as a vital first step, however evidence-based programs have yet to be established. Mental Health First Aid (MHFA) is one of the most well-validated educational programs encouraging lay people such as family members, to support close persons suffering from various psychiatric conditions such as depression, anxiety and suicidal behaviors. Methods: We newly developed an educational program for family members of hikikomori sufferers mainly based on MHFA and 'Community Reinforcement and Family Training (CRAFT)' with role-play and homework. As a single-arm trial, 21 parents (7 fathers and 14 mothers) living with hikikomori sufferers participated in our program with five once-a-week sessions (2 h per session) and six monthly follow-ups, and its effectiveness was evaluated using various self-rated questionnaires. Results: Perceived skills toward a depressed hikikomori case vignette, stigma held by participants, and subscales of two problematic and one adaptive behaviors of hikikomori sufferers were improved throughout the sessions and follow-ups. In addition, positive behavioral changes of hikikomori sufferers such as improved social participation were reported by participants. Limitations: Single-arm design and evaluation using self-rated questionnaires are the main limitations of the present study. Conclusions: Our newly developed program has positive effects on family members in their contact and support of hikikomori sufferers. Future trials with control groups are required to validate the effectiveness of this program.
  • Hashimoto Naoki, Toyomaki Atuhito, Oka Matsuhiko, Takanobu Keisuke, Okubo Ryo, Narita Hisashi, Kitagawa Kan, Udo Niki, Maeda Tamaki, Watanabe Shinya, Oyanagi Yuka, Miyazaki Akane, Ito Koki, Kusumi Ichiro
    Neuropsychiatric Disease and Treatment 15 3511 - 3518 2019/12 [Refereed][Not invited]
  • Koshiyama D, Fukunaga M, Okada N, Morita K, Nemoto K, Usui K, Yamamori H, Yasuda Y, Fujimoto M, Kudo N, Azechi H, Watanabe Y, Hashimoto N, Narita H, Kusumi I, Ohi K, Shimada T, Kataoka Y, Yamamoto M, Ozaki N, Okada G, Okamoto Y, Harada K, Matsuo K, Yamasue H, Abe O, Hashimoto R, Takahashi T, Hori T, Nakataki M, Onitsuka T, Holleran L, Jahanshad N, van Erp TGM, Turner J, Donohoe G, Thompson PM, Kasai K, Hashimoto R, COCORO
    Molecular psychiatry 25 (4) 883 - 895 1359-4184 2019/11 [Refereed][Not invited]
     
    Identifying both the commonalities and differences in brain structures among psychiatric disorders is important for understanding the pathophysiology. Recently, the ENIGMA-Schizophrenia DTI Working Group performed a large-scale meta-analysis and reported widespread white matter microstructural alterations in schizophrenia; however, no similar cross-disorder study has been carried out to date. Here, we conducted mega-analyses comparing white matter microstructural differences between healthy comparison subjects (HCS; N = 1506) and patients with schizophrenia (N = 696), bipolar disorder (N = 211), autism spectrum disorder (N = 126), or major depressive disorder (N = 398; total N = 2937 from 12 sites). In comparison with HCS, we found that schizophrenia, bipolar disorder, and autism spectrum disorder share similar white matter microstructural differences in the body of the corpus callosum; schizophrenia and bipolar disorder featured comparable changes in the limbic system, such as the fornix and cingulum. By comparison, alterations in tracts connecting neocortical areas, such as the uncinate fasciculus, were observed only in schizophrenia. No significant difference was found in major depressive disorder. In a direct comparison between schizophrenia and bipolar disorder, there were no significant differences. Significant differences between schizophrenia/bipolar disorder and major depressive disorder were found in the limbic system, which were similar to the differences in schizophrenia and bipolar disorder relative to HCS. While schizophrenia and bipolar disorder may have similar pathological characteristics, the biological characteristics of major depressive disorder may be close to those of HCS. Our findings provide insights into nosology and encourage further investigations of shared and unique pathophysiology of psychiatric disorders.
  • Yoshikazu Takaesu, Koichiro Watanabe, Shusuke Numata, Masaaki Iwata, Noriko Kudo, Satoru Oishi, Takeya Takizawa, Kiyotaka Nemoto, Yuka Yasuda, Hiromi Tagata, Takashi Tsuboi, Naohisa Tsujino, Naoki Hashimoto, Yuki Matsui, Hikaru Hori, Hidenaga Yamamori, Nobuhiro Sugiyama, Taro Suwa, Taishiro Kishimoto, Akitoyo Hishimoto, Masahide Usami, Ryuji Furihata, Kunihiro Iwamoto, Hiroshige Fujishiro, Toshinori Nakamura, Kentaro Mizuno, Takahiko Inagaki, Eiichi Katsumoto, Hiroaki Tomita, Kazutaka Ohi, Hiroyuki Muraoka, Kiyokazu Atake, Hitoshi Iida, Tatsuya Nagasawa, Junichi Fujita, Satoshi Yamamura, Toshiaki Onitsuka, Atsunobu Murata, Yoichiro Takayanagi, Hokuto Noda, Yukiko Matsumura, Kenji Takezawa, Jun-Ichi Iga, Kayo Ichihashi, Kazuyoshi Ogasawara, Hisashi Yamada, Ken Inada, Ryota Hashimoto
    Psychiatry and clinical neurosciences 73 (10) 642 - 648 1323-1316 2019/10 [Refereed][Not invited]
     
    AIM: Although treatment guidelines for pharmacological therapy for schizophrenia and major depressive disorder have been issued by the Japanese Societies of Neuropsychopharmacology and Mood Disorders, these guidelines have not been well applied by psychiatrists throughout the nation. To address this issue, we developed the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' integrated education programs for psychiatrists to disseminate the clinical guidelines. Additionally, we conducted a systematic efficacy evaluation of the programs. METHODS: Four hundred thirteen out of 461 psychiatrists attended two 1-day educational programs based on the treatment guidelines for schizophrenia and major depressive disorder from October 2016 to March 2018. We measured the participants' clinical knowledge of the treatment guidelines using self-completed questionnaires administered before and after the program to assess the effectiveness of the programs for improving knowledge. We also examined the relation between the participants' demographics and their clinical knowledge scores. RESULTS: The clinical knowledge scores for both guidelines were significantly improved after the program. There was no correlation between clinical knowledge and participant demographics for the program on schizophrenia; however, a weak positive correlation was found between clinical knowledge and the years of professional experience for the program on major depressive disorder. CONCLUSION: Our results provide evidence that educational programs on the clinical practices recommended in guidelines for schizophrenia and major depressive disorder might effectively improve participants' clinical knowledge of the guidelines. These data are encouraging to facilitate the standardization of clinical practices for psychiatric disorders.
  • Kentaro Matsui, Takahiro Tokumasu, Yoshiteru Takekita, Ken Inada, Tetsufumi Kanazawa, Taishiro Kishimoto, Shotaro Takasu, Hideaki Tani, Seiichiro Tarutani, Naoki Hashimoto, Hiroki Yamada, Yoshio Yamanouchi, Hiroyoshi Takeuchi
    Schizophrenia research 209 50 - 57 2019/07 
    BACKGROUND: While recent meta-analyses have reported the superiority of antipsychotic polypharmacy (APP) over antipsychotic monotherapy (APM) in schizophrenia, switching to APM can be beneficial in terms of side effects. To determine whether patients receiving APP should switch to APM or stay on APP, we conducted a systematic review and meta-analysis. METHODS: Randomized controlled trials (RCTs) examining a switch from APP to APM vs. staying on APP were systematically selected from a previous meta-analysis comparing APP with APM in patients with schizophrenia. In addition, we conducted an updated systematic literature search using MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. Data on study discontinuation, relapse, psychopathology, neurocognition, extrapyramidal symptoms, and body weight/body mass index (BMI) were extracted and synthesized. RESULTS: A total of 6 RCTs involving 341 patients were included. All studies examined a switch from 2 antipsychotic agents to a single agent. Clozapine-treated patients were included in 3 studies. There was a significant difference in study discontinuation due to all causes in favor of staying on APP (N = 6, n = 341, RR = 2.28, 95% CI = 1.50-3.46, P < 0.001). There were no significant differences in relapse, any psychopathology, neurocognition, extrapyramidal symptoms, or body weight/BMI between the 2 groups. The quality of evidence was low to very low. CONCLUSIONS: The findings suggest that clinicians should closely monitor patient condition when switching to APM after receiving 2 antipsychotics. Given the low to very low overall quality of the evidence, the findings should be considered preliminary and inconclusive.
  • 日本語版PANSSの信頼性、妥当性評価
    橋本 直樹, 岡 松彦, 高信 径介, 成田 尚, 北川 寛, 宇土 仁木, 前田 珠希, 渡辺 晋也, 大柳 有加, 宮崎 茜, 伊藤 侯輝, 久住 一郎
    精神神経学雑誌 (公社)日本精神神経学会 (2019特別号) S443 - S443 0033-2658 2019/06 [Refereed][Not invited]
  • MianserinからMirtazapineへの置換中にセロトニン症候群が生じた一例
    黒鳥 偉作, 橋本 直樹, 石川 修平, 成田 尚, 久住 一郎
    精神神経学雑誌 (公社)日本精神神経学会 (2019特別号) S600 - S600 0033-2658 2019/06 [Refereed][Not invited]
  • Alzheimer型認知症のBPSDと脳内Dopamine神経系の関連
    宇土 仁木, 橋本 直樹, 中川 伸, 豊永 拓哉, 大柳 有加, 北川 寛, 成田 尚, 久住 一郎
    精神神経学雑誌 (公社)日本精神神経学会 (2019特別号) S618 - S618 0033-2658 2019/06 [Refereed][Not invited]
  • Bifidobacterium breve AIによる統合失調症の不安抑うつ症状に対する効果の検討
    大久保 亮, 古賀 農人, 勝又 紀子, 小田巻 敏孝, 松山 詩菜, 岡 松彦, 成田 尚, 橋本 直樹, 久住 一郎, 清水 金忠
    総合病院精神医学 (一社)日本総合病院精神医学会 30 (Suppl.) S - 131 0915-5872 2018/11
  • Ichiro Kusumi, Yuki Arai, Ryo Okubo, Minoru Honda, YasuhiroMatsuda, Yukihiko Matsuda, Akihiko Tochigi, Yoshiteru Takekita, Hiroyoshi Yamanaka, Keiichi Uemura, Koichi Ito, Kiyoshi Tsuchiya, Jun Yamada, Bunta Yoshimura, Nobuyuki Mitsui, Sigehiro Matsubara, Takayuki Segawa, Nobuyuki Nishi, Yasufumi Sugawara, Yuki Kako, Ikuta Shinkawa, Kaoru Shinohara, Akiko Konishi, Junichi Iga, Naoki Hashimoto, Shinsaku Inomata, Noriko Tsukamoto, Hiroto Ito, Yoichi M. Ito, Norihiro Sato
    BJPsych Open 4 (6) 454 - 460 2056-4724 2018/11 [Refereed][Not invited]
     
    BackgroundPatients with schizophrenia or bipolar disorder have a high risk of developing type 2 diabetes.AimsTo identify predictive factors for hyperglycaemic progression in individuals with schizophrenia or bipolar disorder and to determine whether hyperglycaemic progression rates differ among antipsychotics in regular clinical practice.MethodWe recruited 1166 patients who initially had normal or prediabetic glucose levels for a nationwide, multisite, I-year prospective cohort study to determine predictive factors for hyperglycaemic progression. We also examined whether hyperglycaemic progression varied among patients receiving monotherapy with the six most frequently used anti psychotics.ResultsHigh baseline serum triglycerides and coexisting hypertension significantly predicted hyperglycaemic progression. The six most frequently used antipsychotics did not significantly differ in their associated Hyperglycaemic progression rates over the 1-year observation period.ConclusionsClinicians should carefully evaluate baseline serum triglycerides and coexisting hypertension and perform strict longitudinal monitoring irrespective of the antipsychotic used.
  • Okubo R, Koga M, Katsumata N, Odamaki T, Matsuyama S, Oka M, Narita H, Hashimoto N, Kusumi I, Xiao J, Matsuoka YJ
    Journal of Affective Disorders 2018/11 [Refereed][Not invited]
  • Masaru Tateno, Nikolina Jovanović, Julian Beezhold, Kumi Uehara-Aoyama, Wakako Umene-Nakano, Takashi Nakamae, Naoki Uchida, Naoki Hashimoto, Saya Kikuchi, Yosuke Wake, Daisuke Fujisawa, Keisuke Ikari, Kotaro Otsuka, Katsuyoshi Takahashi, Gaku Okugawa, Norio Watanabe, Tomohiro Shirasaka, Takahiro A Kato
    Early intervention in psychiatry 12 (5) 935 - 937 1751-7885 2018/10 [Refereed][Not invited]
     
    AIM: Burnout is a psychological condition that may occur in all workers after being exposed to excessive work-related stresses. We investigated suicidal ideation and burnout among Japanese psychiatric trainees as a part of the Burnout Syndrome Study (BoSS) International. METHODS: In the Japanese branch, 91 trainees fully completed suicide ideation and behaviour questionnaire (SIBQ) and Maslach Burnout Inventory-General Survey (MBI-GS). RESULTS: Passive suicidal ideation was reported by 38.5% of Japanese trainees and 22.0% of them had experienced active suicidal ideation. The burnout rate among Japanese subjects was 40.0%. These results were worse compared to the all 1980 trainees who fully completed the main outcome measure in BoSS International, 25.9%, 20.4% and 36.7%, respectively. CONCLUSIONS: Our results suggest a higher risk of suicide among Japanese residents. Japan has a higher suicide rate than other countries. Early detection of, and appropriate intervention for, suicidal ideation is important in preventing suicide in psychiatry residents.
  • 高所転落のために多発外傷を受傷した統合失調症症例の検討
    高信 径介, 岡 松彦, 橋本 直樹, 伊藤 侯輝, 久住 一郎
    精神神経学雑誌 (公社)日本精神神経学会 120 (8) 722 - 722 0033-2658 2018/08
  • Naoki Hashimoto, Atsuhito Toyomaki, Tamaki Miyamoto, Akane Miyazaki, Ichiro Kuksumi
    Schizophrenia Research 197 587 - 588 1573-2509 2018/07/01 [Refereed][Not invited]
  • 岡田直大, 福永雅喜, 山森英長, 安田由華, 橋本直樹, 中瀧理仁, 大井一高, 肥田道彦, 宮田淳, 高橋努, 根本清貴, 松尾幸治, 鬼塚俊明, 橋本龍一郎, 岡本泰昌, 山末英典, 山末英典, 吉村玲児, 尾崎紀夫, 笠井清登, 橋本亮太, 橋本亮太
    統合失調症研究 8 (1) 120  2018/03/01 [Not refereed][Not invited]
  • Hiroaki Kubo, Hiromi Urata, Ryoko Katsuki, Miyako Hirashima, Shion Ueno, Yuriko Suzuki, Daisuke Fujisawa, Naoki Hashimoto, Keiji Kobara, Tetsuji Cho, Toshiko Mitsui, Shigenobu Kanba, Kotaro Otsuka, Takahiro A Kato
    PloS one 13 (12) e0208114  2018 [Not refereed][Not invited]
     
    OBJECTIVE: In the workplace depression and suicide are serious mental health problems. A lack of knowledge and mental health skills along with the stigma toward mental health problems often results in delays in seeking professional help. Interventions targeting not only persons with mental health problems but also people around the individual are warranted in order to encourage supporting behavior within entire workplace. In the present study, we investigated the efficacy of our newly developed educational training program in the management with depression and suicidal risk in the workplace as a single-arm pilot trial. METHODS: The program is a two-hour (2-h) training course for employees based on the Mental Health First Aid (MHFA) program which aims to increase public mental health literacy. We conducted this program at a company workplace among 91 employees, and ultimately 83 participants completed the self-rated questionnaires. Changes in confidence and practical skills in early intervention of depression and suicide-prevention, and stigma toward mental health problems were evaluated using self-rated questionnaires at 3 time-points; pre-program, immediately post-program, and 1 month after the program. RESULTS: Confidence and practical skills were significantly improved even 1 month after the program, and stigma reduced just after the program. CONCLUSIONS: Our pilot study suggests that the program has a positive impact on encouraging employees to support their co-workers with mental health problems, and is applicable for busy workers due to its short duration. A single-arm design, evaluation using self-rated questionnaire and short-term follow up period are the main limitations of the present study. Hence, future research is required to validate the effects of this program with control groups, and also to assess long-term effectiveness and objective changes such as absenteeism and sick leave. TRIAL REGISTRATION: UMIN Clinical Trials Registry (UMIN-CTR) R000023258.
  • Yukako Nakagami, Hiroaki Kubo, Ryoko Katsuki, Tomomichi Sakai, Genichi Sugihara, Chisako Naito, Hiroyuki Oda, Kohei Hayakawa, Yuriko Suzuki, Daisuke Fujisawa, Naoki Hashimoto, Keiji Kobara, Tetsuji Cho, Hironori Kuga, Kiyoshi Takao, Yoko Kawahara, Yumi Matsumura, Toshiya Murai, Koichi Akashi, Shigenobu Kanba, Kotaro Otsuka, Takahiro A Kato
    Journal of affective disorders 225 569 - 576 0165-0327 2018/01/01 [Refereed][Not invited]
     
    BACKGROUND: Suicide is a crucial global health concern and effective suicide prevention has long been warranted. Mental illness, especially depression is the highest risk factor of suicide. Suicidal risk is increased in people not only with mental illness but also with physical illnesses, thus medical staff caring for physically-ill patients are also required to manage people with suicidal risk. In the present study, we evaluated our newly developed suicide intervention program among medical staff. METHODS: We developed a 2-h suicide intervention program for medical staff, based on the Mental Health First Aid (MHFA), which had originally been developed for the general population. We conducted this program for 74 medical staff members from 2 hospitals. Changes in knowledge, perceived skills, and confidence in early intervention of depression and suicide-prevention were evaluated using self-reported questionnaires at 3 points; pre-program, immediately after the program, and 1 month after program. RESULTS: This suicide prevention program had significant effects on improving perceived skills and confidence especially among nurses and medical residents. These significant effects lasted even 1 month after the program. LIMITATIONS: Design was a single-arm study with relatively small sample size and short-term follow up. CONCLUSIONS: The present study suggests that the major target of this effective program is nurses and medical residents. Future research is required to validate the effects of the program with control groups, and also to assess long-term effectiveness and actual reduction in suicide rates.
  • Naoki Hashimoto, Yoichi M Ito, Naohiro Okada, Hidenaga Yamamori, Yuka Yasuda, Michiko Fujimoto, Noriko Kudo, Ariyoshi Takemura, Shuraku Son, Hisashi Narita, Maeri Yamamoto, Khin Khin Tha, Asuka Katsuki, Kazutaka Ohi, Fumio Yamashita, Shinsuke Koike, Tsutomu Takahashi, Kiyotaka Nemoto, Masaki Fukunaga, Toshiaki Onitsuka, Yoshiyuki Watanabe, Hidenori Yamasue, Michio Suzuki, Kiyoto Kasai, Ichiro Kusumi, Ryota Hashimoto
    NeuroImage. Clinical 17 563 - 569 2018 [Refereed][Not invited]
     
    Background: The effect of duration of illness and antipsychotic medication on the volumes of subcortical structures in schizophrenia is inconsistent among previous reports. We implemented a large sample analysis utilizing clinical data from 11 institutions in a previous meta-analysis. Methods: Imaging and clinical data of 778 schizophrenia subjects were taken from a prospective meta-analysis conducted by the COCORO consortium in Japan. The effect of duration of illness and daily dose and type of antipsychotics were assessed using the linear mixed effect model where the volumes of subcortical structures computed by FreeSurfer were used as a dependent variable and age, sex, duration of illness, daily dose of antipsychotics and intracranial volume were used as independent variables, and the type of protocol was incorporated as a random effect for intercept. The statistical significance of fixed-effect of dependent variable was assessed. Results: Daily dose of antipsychotics was positively associated with left globus pallidus volume and negatively associated with right hippocampus. It was also positively associated with laterality index of globus pallidus. Duration of illness was positively associated with bilateral globus pallidus volumes. Type of antipsychotics did not have any effect on the subcortical volumes. Discussion: A large sample size, uniform data collection methodology and robust statistical analysis are strengths of the current study. This result suggests that we need special attention to discuss about relationship between subcortical regional brain volumes and pathophysiology of schizophrenia because regional brain volumes may be affected by antipsychotic medication.
  • Ryo Okubo, Takeshi Inoue, Naoki Hashimoto, Akio Suzukawa, Hajime Tanabe, Matsuhiko Oka, Hisashi Narita, Koki Ito, Yuki Kako, Ichiro Kusumi
    PSYCHIATRY RESEARCH 257 126 - 131 0165-1781 2017/11 [Refereed][Not invited]
     
    Previous studies indicated that personality traits have a mediator effect on the relationship between childhood abuse and depressive symptoms in major depressive disorder and nonclinical general adult subjects. In the present study, we aimed to test the hypothesis that personality traits mediate the relationship between childhood abuse and depressive symptoms in schizophrenia. We used the following questionnaires to evaluate 255 outpatients with schizophrenia: the Child Abuse and Trauma Scale, temperament and character inventory, and Patients Health Questionnire-9. Univariate analysis, multiple regression analysis, and structured equation, modeling (SEM) were used to analyze the data. The relationship between neglect and sexual abuse and the severity of depressive symptoms was mostly mediated by the personality traits of high harm avoidance, low self-directedness, and low cooperativeness. This finding was supported by the results of stepwise multiple regression analysis and the acceptable fit indices of SEM. Thus, our results suggest that personality traits mediate the relationship between childhood abuse and depressive symptoms in schizophrenia. The present study and our previous studies also suggest that this mediator effect could occur independent of the presence or type of mental disorder. Clinicians should routinely assess childhood abuse history, personality traits, and their effects in schizophrenia.
  • 認知機能改善療法が手を用いる作業能力に与える効果に関する予備的検討 Purdue Pegboad testの結果比較から
    井上 貴雄, 武井 早紀, 豊巻 敦人, 橋本 直樹, 久住 一郎
    日本作業療法学会抄録集 (一社)日本作業療法士協会 51回 SS9 - 3 1880-6635 2017/09
  • Ryo Sawagashira, Hisashi Narita, Naoki Hashimoto, Tsugiko Kurita, Shin Nakagawa, Takuya Saitoh, Ichiro Kusumi
    EPILEPTIC DISORDERS 19 (3) 379 - 382 1294-9361 2017/09 [Refereed][Not invited]
     
    Transient lesions of the splenium of the corpus callosum are characterized by MRI findings. The lesions are very rare, but significant from a clinical standpoint as differential diagnoses include serious conditions such as encephalitis, meningitis, and neuroleptic malignant syndrome. In addition, it is reported that some are attributed to the withdrawal of antiepileptic drugs. Here, we present a case of transient lesions of the splenium of the corpus callosum following rapid withdrawal of levetiracetam alone. To the best of our knowledge, this is the first report of such a case. Moreover, it is reported that cases of incidental transient lesions of the splenium of the corpus callosum are detected in Japan more often than in other countries, and as a result are prone to over-triage. Taking this into consideration, in the event of transient lesions of the splenium of the corpus callosum, the utmost attention must be paid to clinical symptoms and history relating to any of the aforementioned serious conditions.
  • Atsuhito Toyomaki, Naoki Hashimoto, Yuki Kako, Harumitsu Murohashi, Ichiro Kusumi
    PLOS ONE 12 (8) e0183792  1932-6203 2017/08 [Refereed][Not invited]
     
    Several studies of self-monitoring dysfunction in schizophrenia have focused on the sense of agency to motor action using behavioral and psychophysiological techniques. So far, no study has ever tried to investigate whether the sense of agency or causal attribution for external events produced by self-generated decision-making is abnormal in schizophrenia. The purpose of this study was to investigate neural responses to feedback information produced by self-generated or other-generated decision-making in a multiplayer gambling task using even-related potentials and electroencephalogram synchronization. We found that the late positive component and theta/alpha synchronization were increased in response to feedback information in the self-decision condition in normal controls, but that these responses were significantly decreased in patients with schizophrenia. These neural activities thus reflect the self-reference effect that affects the cognitive appraisal of external events following decision-making and their impairment in schizophrenia.
  • Takeo Saito, Masashi Ikeda, Ryota Hashimoto, Nakao Iwata, Hidenaga Yamamori, Yuka Yasuda, Michiko Fujimoto, Kenji Kondo, Ayu Shimasaki, Kohei Kawase, Masami Miyata, Taisei Mushiroda, Takeshi Ozeki, Michiaki Kubo, Kiyoshi Fujita, Naoya Kida, Minori Nakai, Taku Otsuru, Yasuhide Fukuji, Masaru Murakami, Kentaro Mizuno, Toshiaki Shiratsuchi, Shusuke Numata, Tetsuro Ohmori, Shu-Ichi Ueno, Yuji Yada, Sadakazu Tanaka, Yoshiki Kishi, Manabu Takaki, Akiko Mamoto, Norio Taniguchi, Yutaka Sawa, Haruo Watanabe, Tetsuro Noda, Yuuhei Amano, Takemi Kimura, Taku Fukao, Taro Suwa, Toshiya Murai, Masaharu Kubota, Keishi Ueda, Hideaki Tabuse, Nobuhisa Kanahara, Nobutoshi Kawai, Kiyotaka Nemoto, Manabu Makinodan, Yosuke Nishihata, Naoki Hashimoto, Ichiro Kusumi, Yasuo Fujii, Ryoji Miyata, Kyuryoku Hirakawa, Norio Ozaki
    Biological psychiatry 82 (1) e9-e10 - e10 0006-3223 2017/07/01 [Refereed][Not invited]
  • Haruo Fujino, Chika Sumiyoshi, Yuka Yasuda, Hidenaga Yamamori, Michiko Fujimoto, Masaki Fukunaga, Kenichiro Miura, Yuto Takebayashi, Naohiro Okada, Shuichi Isomura, Naoko Kawano, Atsuhito Toyomaki, Hironori Kuga, Masanori Isobe, Kazuto Oya, Yuko Okahisa, Manabu Takaki, Naoki Hashimoto, Masaki Kato, Toshiaki Onitsuka, Takefumi Ueno, Tohru Ohnuma, Kiyoto Kasai, Norio Ozaki, Tomiki Sumiyoshi, Osamu Imura, Ryota Hashimoto
    PSYCHIATRY AND CLINICAL NEUROSCIENCES 71 (5) 294 - 300 1323-1316 2017/05 [Refereed][Not invited]
     
    Aim: Studies have reported that cognitive decline occurs after the onset of schizophrenia despite heterogeneity in cognitive function among patients. The aim of this study was to investigate the degree of estimated cognitive decline in patients with schizophrenia by comparing estimated premorbid intellectual functioning and current intellectual functioning. Methods: A total of 446 patients with schizophrenia (228 male, 218 female), consisting of three sample sets obtained from 11 psychiatric facilities, and 686 healthy controls participated in this study. The Wechsler Adult Intelligence Scale-III (WAIS-III) was used to measure the participants' current full-scale IQ (FSIQ). The premorbid IQ was estimated using the Japanese Adult Reading Test-25. Estimated cognitive decline (difference score) was defined as the difference between the estimated premorbid IQ and the current FSIQ. Results: Patients with schizophrenia showed greater estimated cognitive decline, a lower FSIQ, and a lower premorbid IQ compared with the healthy controls. The mean difference score, FSIQ, and estimated premorbid IQ were -16.3, 84.2, and 100.5, respectively, in patients with schizophrenia. Furthermore, 39.7% of the patients had a difference score of 20 points or greater decline. A discriminant analysis showed that the difference score accurately predicted 81.6% of the patients and healthy controls. Conclusion: These results show the distribution of difference score in patients with schizophrenia. These findings may contribute to assessing the severity of estimated cognitive decline and identifying patients with schizophrenia who suffer from cognitive decline.
  • Hisashi Narita, Khin K Tha, Naoki Hashimoto, Hiroyuki Hamaguchi, Shin Nakagawa, Hiroki Shirato, Ichiro Kusumi
    Progress in neuro-psychopharmacology & biological psychiatry 71 169 - 75 0278-5846 2016/11/03 [Refereed][Not invited]
     
    INTRODUCTION: Diffusion kurtosis imaging can provide a better understanding of microstructural white matter (WM) changes where crossing fibers exist, compared with conventional diffusion tensor imaging. Here, we aimed to examine the differences of mean kurtosis (MK) and fractional anisotropy (FA) values between patients with schizophrenia and control subjects using voxel-based analysis (VBA). Additionally, we examined the correlation between these values and severity of clinical symptoms in patients with schizophrenia. METHODS: MK and FA values were acquired with a 3.0T scanner from 31 patients with schizophrenia and 31 age-, handedness-, and sex-matched healthy controls. VBA was used to compare the MK and FA maps of the patients with schizophrenia and healthy controls. We also performed a correlation analysis between the MK and FA values of the regions with significant differences and the positive and negative syndrome scale scores in patients with schizophrenia. RESULTS: Compared to FA values, voxels with MK decrease were more widespread across bilateral cerebral the WM of patients with schizophrenia. The MK values of left superior longitudinal fasciculus were significantly negatively correlated with the severity of positive symptoms (r=-0.451, P=0.011). There was no significant correlation between MK and FA values and other clinical variables. CONCLUSION: The diffusion kurtosis indices are suitable for evaluating altered WM structures in the human brain as they may detect white matter alterations of crossing fibers alterations of WM in schizophrenia and assess the clinical state of patients.
  • Takeo Saito, Masashi Ikeda, Taisei Mushiroda, Takeshi Ozeki, Kenji Kondo, Ayu Shimasaki, Kohei Kawase, Shuji Hashimoto, Hidenaga Yamamori, Yuka Yasuda, Michiko Fujimoto, Kazutaka Ohi, Masatoshi Takeda, Yoichiro Kamatani, Shusuke Numata, Tetsuro Ohmori, Shu-ichi Ueno, Manabu Makinodan, Yosuke Nishihata, Masaharu Kubota, Takemi Kimura, Nobuhisa Kanahara, Naoki Hashimoto, Kiyoshi Fujita, Kiyotaka Nemoto, Taku Fukao, Taro Suwa, Tetsuro Noda, Yuji Yada, Manabu Takaki, Naoya Kida, Taku Otsuru, Masaru Murakami, Atsushi Takahashi, Michiaki Kubo, Ryota Hashimoto, Nakao Iwata
    BIOLOGICAL PSYCHIATRY 80 (8) 636 - 642 0006-3223 2016/10 [Refereed][Not invited]
     
    BACKGROUND: Clozapine-induced agranulocytosis (CIA)/clozapine-induced granulocytopenia (CIG) (CIAG) is a life-threatening event for schizophrenic subjects treated with clozapine. METHODS: To examine the genetic factor for CIAG, a genome-wide pharmacogenomic analysis was conducted using 50 subjects with CIAG and 2905 control subjects. RESULTS: We identified a significant association in the human leukocyte antigen (HLA) region (rs1800625, p = 3.46 x 10(-9), odds ratio [OR] = 3.8); therefore, subsequent HLA typing was performed. We detected a significant association of HLA-B*59:01 with CIAG (p = 3.81 x 10(-8), OR = 10.7) and confirmed this association by comparing with an independent clozapine-tolerant control group (n = 380, p = 2.97 x 10(-5), OR = 6.3). As we observed that the OR of CIA (OR: 9.3 similar to 15.8) was approximately double that in CIG (OR: 4.4 similar to 7.4), we hypothesized that the CIG subjects were a mixed population of those who potentially would develop CIA and those who would not develop CIA (non-CIA). This hypothesis allowed the proportion of the CIG who were non-CIA to be calculated, enabling us to estimate the positive predictive value of the nonrisk allele on non-CIA in CIG subjects. Assuming this model, we estimated that 1) similar to 50% of CIG subjects would be non-CIA; and 2) similar to 60% of the CIG subjects without the risk allele would be non-CIA and therefore not expected to develop CIA. CONCLUSIONS: Our results suggest that HLA-B*59:01 is a risk factor for CIAG in the Japanese population. Furthermore, if our model is true, the results suggest that rechallenging certain CIG subjects with clozapine may not be always contraindicated.
  • Hiroyuki Toda, Takeshi Inoue, Tomoya Tsunoda, Yukiei Nakai, Masaaki Tanichi, Teppei Tanaka, Naoki Hashimoto, Yoshikazu Takaesu, Shin Nakagawa, Yuji Kitaichi, Shuken Boku, Hajime Tanabe, Masashi Nibuya, Aihide Yoshino, Ichiro Kusumi
    PSYCHIATRY RESEARCH 236 142 - 147 0165-1781 2016/02 [Refereed][Not invited]
     
    Previous studies have shown that various factors, such as genetic and environmental factors, contribute to the development of major depressive disorder (MDD). The aim of this study is to clarify how multiple factors, including affective temperaments, childhood abuse and adult life events, are involved in the severity of depressive symptoms in MDD. A total of 98 participants with MDD were studied using the following self-administered questionnaire surveys: Patient Health Questionnaire-9 measuring the severity of depressive symptoms; Life Experiences Survey (LES) measuring negative and positive adult life events; Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego auto-questionnaire (TEMPS A) measuring affective temperaments; and the Child Abuse and Trauma Scale (CATS) measuring childhood abuse. The data were analyzed using single and multiple regression analyses and structural equation modeling (SEM). The neglect score reported by CATS indirectly predicted the severity of depressive symptoms through affective temperaments measured by TEMPS-A in SEM. Four temperaments (depressive, cyclothymic, irritable, and anxious) directly predicted the severity of depressive symptoms. The negative change in the LES score also directly predicted severity. This study suggests that childhood abuse, especially neglect, indirectly increases the severity of depressive symptoms through increased scores of affective temperaments in MDD. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
  • Okada N, Fukunaga M, Yamashita F, Koshiyama D, Yamamori H, Ohi K, Yasuda Y, Fujimoto M, Watanabe Y, Yahata N, Nemoto K, Hibar DP, van Erp TGM, Fujino H, Isobe M, Isomura S, Natsubori T, Narita H, Hashimoto N, Miyata J, Koike S, Takahashi T, Yamasue H, Matsuo K, Onitsuka T, Iidaka T, Kawasaki Y, Yoshimura R, Watanabe Y, Suzuki M, Turner JA, Takeda M, Thompson PM, Ozaki N, Kasai K, Hashimoto R, COCORO
    Molecular Psychiatry Nature Publishing Group 21 (10) 1460 - 1466 1359-4184 2016/01 [Refereed][Not invited]
     
    Subcortical structures, which include the basal ganglia and parts of the limbic system, have key roles in learning, motor control and emotion, but also contribute to higher-order executive functions. Prior studies have reported volumetric alterations in subcortical regions in schizophrenia. Reported results have sometimes been heterogeneous, and few large-scale investigations have been conducted. Moreover, few large-scale studies have assessed asymmetries of subcortical volumes in schizophrenia. Here, as a work completely independent of a study performed by the ENIGMA consortium, we conducted a large-scale multisite study of subcortical volumetric differences between patients with schizophrenia and controls. We also explored the laterality of subcortical regions to identify characteristic similarities and differences between them. T1-weighted images from 1680 healthy individuals and 884 patients with schizophrenia, obtained with 15 imaging protocols at 11 sites, were processed with FreeSurfer. Group differences were calculated for each protocol and meta-analyzed. Compared with controls, patients with schizophrenia demonstrated smaller bilateral hippocampus, amygdala, thalamus and accumbens volumes as well as intracranial volume, but larger bilateral caudate, putamen, pallidum and lateral ventricle volumes. We replicated the rank order of effect sizes for subcortical volumetric changes in schizophrenia reported by the ENIGMA consortium. Further, we revealed leftward asymmetry for thalamus, lateral ventricle, caudate and putamen volumes, and rightward asymmetry for amygdala and hippocampal volumes in both controls and patients with schizophrenia. Also, we demonstrated a schizophrenia-specific leftward asymmetry for pallidum volume. These findings suggest the possibility of aberrant laterality in neural pathways and connectivity patterns related to the pallidum in schizophrenia.
  • 大久保亮, 橋本直樹, 草地麻実, 成田尚, 久住一郎
    精神神経学雑誌 日本精神神経学会 118 (10) 735 - 743 0033-2658 2016 [Not refereed][Not invited]
  • Naoki Hashimoto, Yuriko Suzuki, Takahiro A Kato, Daisuke Fujisawa, Ryoko Sato, Kumi Aoyama-Uehara, Maiko Fukasawa, Satoshi Asakura, Ichiro Kusumi, Kotaro Otsuka
    Psychiatry and clinical neurosciences 70 (1) 62 - 70 1323-1316 2016/01 [Refereed][Not invited]
     
    AIMS: Suicide is a leading cause of death among Japanese college and university students. Gatekeeper-training programs have been shown to improve detection and referral of individuals who are at risk of suicide by training non-mental-health professional persons. However, no studies have investigated the effectiveness of such programs in university settings in Japan. The aim of this study was to investigate the effectiveness of the gatekeeper-training program for administrative staff in Japanese universities. METHODS: We developed a 2.5-h gatekeeper-training program based on the Mental Health First Aid program, which was originally developed for the general public. Seventy-six administrative staff at Hokkaido University participated in the program. Competence and confidence in managing suicide intervention, behavioral intention as a gatekeeper and attitude while handling suicidal students were measured by a self-reported questionnaire before, immediately after and a month after the program. RESULTS: We found a significant improvement in competence in the management of suicidal students. We also found improvements in confidence in management of suicidal students and behavioral intention as a gatekeeper after training, though questionnaires for those secondary outcomes were not validated. These improvements continued for a month. About 95% of the participants rated the program as useful or very useful and one-third of the participants had one or more chances to utilize their skills within a month. CONCLUSIONS: The current results suggest the positive effects of the training program in university settings in Japan. Future evaluation that includes comparison with standard didactic trainings and an assessment of long-term effectiveness are warranted.
  • Atsuhito Toyomaki, Naoki Hashimoto, Yuki Kako, Yoshiro Tomimatsu, Tsukasa Koyama, Ichiro Kusumi
    Schizophrenia Research: Cognition 2 (3) 166 - 169 2215-0013 2015/09/01 [Refereed][Not invited]
     
    The P50 is an early component of auditory evoked potentials and a measure of sensory gating deficits. This evoked potential component is thought to be an important endophenotype candidate for schizophrenia. Recent research suggests that instead of the P50 ratio, S1 and S2 amplitudes should be evaluated for sensory gating. However, no studies have focused on the relationship between cognitive dysfunction and P50 sensory gating deficits using S1 and S2 amplitudes. The purpose of the present study was to investigate the association between the P50 ratio (S2/S1), S1 and S2 amplitudes, and neuropsychological cognitive domains using stepwise multiple linear regression analyses. Results demonstrated a significant relationship between executive functioning and the P50 ratio and between sustained attention and S2 amplitude, respectively. Our findings suggest that the P50 ratio and S2 amplitude reflect distinct neurophysiological substrates associated with different cognitive functions.
  • Naoki Hashimoto, Daisuke Fujisawa, Noor Ahmed Giasuddin, Basanth Kumar Kenchaiah, Altanzul Narmandakh, Khongorzul Dugerragchaa, Sharad Man Tamrakar, Shailendra Raj Adhikari, Norman Sartorius
    ASIA-PACIFIC JOURNAL OF PUBLIC HEALTH 27 (2) NP1847 - NP1857 1010-5395 2015/03 [Refereed][Not invited]
     
    Introduction: As mental health systems are still developing in many Asian countries, knowledge of the pathways to mental health care (MHC) in this region would be very important. Aims: To clarify the pathways to MHC in 5 Asian countries. Method: A total of 50 new subjects attending each institution were interviewed. Pathway diagrams, the patterns and duration of care seeking, and the previous treatment were compared. Results: Four major pathways were direct access, referrals from private practitioners, referrals from general hospitals, and referrals from native or religious healers. General practitioners did not play a pivotal role in any of the areas, whereas native or religious healers had an important place in all areas except for Yokohama, Japan. Family members had a significant impact on the decision to seek MHC. Conclusions: Studies of pathways to MHC in Asian countries are feasible and can provide data of interest in the organization of care.
  • Naoki Hashimoto, Tamaki Maeda, Ryo Okubo, Hisashi Narita, Ichiro Kusumi
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY 35 (1) 99 - 101 0271-0749 2015/02 [Refereed][Not invited]
  • Hiroyuki Toda, Takeshi Inoue, Tomoya Tsunoda, Yukiei Nakai, Masaaki Tanichi, Teppei Tanaka, Naoki Hashimoto, Yasuya Nakato, Shin Nakagawa, Yuji Kitaichi, Nobuyuki Mitsui, Shuken Boku, Hajime Tanabe, Masashi Nibuya, Aihide Yoshino, Ichiro Kusumi
    NEUROPSYCHIATRIC DISEASE AND TREATMENT 11 2079 - 2090 1178-2021 2015 [Refereed][Not invited]
     
    Background: Previous studies have shown the interaction between heredity and childhood stress or life events on the pathogenesis of a major depressive disorder (MDD). In this study, we tested our hypothesis that childhood abuse, affective temperaments, and adult stressful life events interact and influence the diagnosis of MDD.Patients and methods: A total of 170 healthy controls and 98 MDD patients were studied using the following self-administered questionnaire surveys: the Patient Health Questionnaire-9 (PHQ-9), the Life Experiences Survey, the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire, and the Child Abuse and Trauma Scale (CATS). The data were analyzed with univariate analysis, multivariable analysis, and structural equation modeling.Results: The neglect scores of the CATS indirectly predicted the diagnosis of MDD through cyclothymic and anxious temperament scores of the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire in the structural equation modeling. Two temperaments - cyclothymic and anxious - directly predicted the diagnosis of MDD. The validity of this result was supported by the results of the stepwise multivariate logistic regression analysis as follows: three factors - neglect, cyclothymic, and anxious temperaments - were significant predictors of MDD. Neglect and the total CATS scores were also predictors of remission vs treatment-resistance in MDD patients independently of depressive symptoms.Limitations: The sample size was small for the comparison between the remission and treatment-resistant groups in MDD patients in multivariable analysis.Conclusion: This study suggests that childhood abuse, especially neglect, indirectly predicted the diagnosis of MDD through increased affective temperaments. The important role as a mediator of affective temperaments in the effect of childhood abuse on MDD was suggested.
  • Naoki Hashimoto, Atsuhito Toyomaki, Minoru Honda, Satoru Miyano, Nobuyuki Nitta, Hiroyuki Sawayama, Yasufumi Sugawara, Keiichi Uemura, Noriko Tsukamoto, Tsukasa Koyama, Ichiro Kusumi
    ANNALS OF GENERAL PSYCHIATRY 14 (1) 1  1744-859X 2015/01 [Refereed][Not invited]
     
    Background: While the frequency and importance of antipsychotic switching in patients with schizophrenia, there is insufficient evidence with regard to switching strategy. Quetiapine is one of the drugs of choice for switch because of its unique receptor profile. However, there were no data on the long-term clinical and neurocognitive effect of quetiapine in patients who had responded inadequately to prior antipsychotics. The purpose of this study is to examine the long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response. We hypothesized that quetiapine would show long-term effectiveness in broad symptom dimensions including negative and neurocognitive symptoms while having good tolerability. Methods: Twenty-nine subjects with schizophrenia who did not respond to their current monotherapy of antipsychotic or who could not tolerate the treatment were switched to quetiapine and assessed at baseline and at 3, 6, and 12 months. The outcome measures included the brief assessment of cognition in schizophrenia (BACS), the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions Scale (CGI), the Schizophrenia Quality of Life Scale Japanese version (JSQLS), the Athens Insomnia Scale (AIS), and the Drug Attitude Inventory with 30 items (DAI-30). The Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS), HbA1c, prolactin (PRL), and body weight were also evaluated. Results: Statistically significant improvements were observed in all subscores of the PANSS, the GAF, and the symptoms and side effects subscale of the JSQLS, the DIEPSS, the AIS, and the PRL level, and nearly significant improvements were observed in the DAI-30. Quetiapine monotherapy was associated with significant improvement in the verbal memory test, even after controlling for the practice effect. Although quetiapine was well tolerated, three subjects dropped out because of the worsening of the psychotic symptoms and two additional subjects dropped out because of somnolence. Conclusion: In this open-label, single-arm study of 29 patients, quetiapine improved both the clinical symptoms and the neurocognitive impairment in chronic schizophrenia patients who failed to respond to prior antipsychotic treatment.
  • Hiroyuki Toda, Takeshi Inoue, Tomoya Tsunoda, Yukiei Nakai, Masaaki Tanichi, Teppei Tanaka, Naoki Hashimoto, Yasuya Nakato, Shin Nakagawa, Yuji Kitaichi, Nobuyuki Mitsui, Shuken Boku, Hajime Tanabe, Masashi Nibuya, Aihide Yoshino, Ichiro Kusumi
    Neuropsychiatric disease and treatment 11 2079 - 90 1176-6328 2015 [Refereed][Not invited]
     
    BACKGROUND: Previous studies have shown the interaction between heredity and childhood stress or life events on the pathogenesis of a major depressive disorder (MDD). In this study, we tested our hypothesis that childhood abuse, affective temperaments, and adult stressful life events interact and influence the diagnosis of MDD. PATIENTS AND METHODS: A total of 170 healthy controls and 98 MDD patients were studied using the following self-administered questionnaire surveys: the Patient Health Questionnaire-9 (PHQ-9), the Life Experiences Survey, the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire, and the Child Abuse and Trauma Scale (CATS). The data were analyzed with univariate analysis, multivariable analysis, and structural equation modeling. RESULTS: The neglect scores of the CATS indirectly predicted the diagnosis of MDD through cyclothymic and anxious temperament scores of the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire in the structural equation modeling. Two temperaments - cyclothymic and anxious - directly predicted the diagnosis of MDD. The validity of this result was supported by the results of the stepwise multivariate logistic regression analysis as follows: three factors - neglect, cyclothymic, and anxious temperaments - were significant predictors of MDD. Neglect and the total CATS scores were also predictors of remission vs treatment-resistance in MDD patients independently of depressive symptoms. LIMITATIONS: The sample size was small for the comparison between the remission and treatment-resistant groups in MDD patients in multivariable analysis. CONCLUSION: This study suggests that childhood abuse, especially neglect, indirectly predicted the diagnosis of MDD through increased affective temperaments. The important role as a mediator of affective temperaments in the effect of childhood abuse on MDD was suggested.
  • 橋本直樹, 小山司, 近藤健, 斉藤拓, 大久保亮, 成田尚, 久住一郎
    精神神経学雑誌 116 (12) 1042  0033-2658 2014/12/25 [Not refereed][Not invited]
  • Naoki Hashimoto, Atsuhito Toyomaki, Masahiro Hirai, Tamaki Miyamoto, Hisashi Narita, Ryo Okubo, Ichiro Kusumi
    Neuropsychiatric Disease and Treatment 10 2221 - 2230 1178-2021 2014/11/17 [Refereed][Not invited]
     
    Background: Patients with schizophrenia show disturbances in both visual perception and social cognition. Perception of biological motion (BM) is a higher-level visual process, and is known to be associated with social cognition. BM induces activation in the “social brain network”, including the superior temporal sulcus (STS). Although deficits in the detection of BM and atypical activation in the STS have been reported in patients with schizophrenia, it remains unclear whether other nodes of the “social brain network” are also atypical in patients with schizophrenia Purpose: We aimed to explore whether brain regions other than STS were involved during BM perception in patients with schizophrenia, using functional magnetic resonance imaging (fMRI). Methods and patients: Seventeen patients with schizophrenia, and 17 ageand sexmatched healthy controls, underwent fMRI scanning during a one-back visual task, containing three experimental conditions: (1) BM, (2) scrambled motion (SM), and (3) static condition. We used one-sample t-tests to examine neural responses selective to BM versus SM within each group, and two-sample t-tests to directly compare neural patterns to BM versus SM in schizophrenics versus controls Results: We found significant activation in the STS region when BM was contrasted with SM in both groups, with no significant difference between groups. On the contrary, significant activation in the medial prefrontal cortex (MPFC) and bilateral temporoparietal junction (TPJ) was found only in the control group. When we directly compared the two groups, the healthy controls showed significant greater activation in left MPFC and TPJ to BM versus SM than patients with schizophrenia Conclusion: Our findings suggest that patients with schizophrenia show normal activation to biologically and socially relevant motion stimuli in the STS, but atypical activation in other regions of the social brain network, specifically MPFC and TPJ. Moreover, these results were not due to atypical processing of motion, suggesting that patients with schizophrenia lack in the recruitment of neural circuits needed for the visual perception of social cognition.
  • Okubo Ryo, Hashimoto Naoki, Itou Kahori, Shirasaka Tomohiro, Kusaka Naohumi, Tateno Masaru, Kusumi Ichiro
    EARLY INTERVENTION IN PSYCHIATRY 8 91  1751-7885 2014/11 [Refereed][Not invited]
  • Shunsuke Onodera, Hidefumi Aoyama, Khin Khin Tha, Naoki Hashimoto, Atsuhito Toyomaki, Satoshi Terae, Hiroki Shirato
    JOURNAL OF NEURO-ONCOLOGY 120 (2) 311 - 319 0167-594X 2014/11 [Refereed][Not invited]
     
    To investigate whether the neurocognitive function at 4 months could be a relevant primary endpoint in clinical trials dealing with brain metastases, we created a Japanese neurocognitive battery and examined the changes in patients' neurocognitive function for 1 year after their brain radiotherapy. In this prospective pilot study, we enrolled 27 patients (20 patients who received whole-brain radiation therapy [WBRT] and seven who received stereotactic irradiation [STI] alone) between March 2009 and December 2010. The follow-up neurocognitive data at 4, 8 and 12 months were available in 22 (17 WBRT, 5 STI), 19 patients (14 WBRT, 5 STI) and 13 patients (9 WBRT, 4 STI), respectively. Among the patients who received WBRT, significant deterioration in delayed memory compared to the baseline (p = 0.04) was observed at 4 months, and at 8 months, significant improvements were observed in immediate memory compared to the baseline (p = 0.008) and 4-months scores (p = 0.005). At 12 months, however, the immediate memory scores had returned to the baseline. Similar trends were observed in other functions (delayed memory, attention and executive functions). In these patients, the correlations between 4-months scores of neurocognitive functions and 12-months scores were significant in immediate memory (gamma = 0.68, p = 0.004), delayed memory (gamma = 0.738, p = 0.023) and attention (gamma = 0.817, p = 0.007). Among the patients who received STI, no significant changes were observed in any functions. These results suggest that 4-months changes in neurocognitive functions were transient but could also be a premonitory index for predicting the neurocognitive function 1 year or later after brain radiation therapy.
  • Yuki Kako, Koki Ito, Naoki Hashimoto, Kuniyoshi Toyoshima, Yusuke Shimizu, Nobuyuki Mitsui, Yutaka Fujii, Teruaki Tanaka, Ichiro Kusumi
    Neuropsychiatric Disease and Treatment 10 1415 - 1422 1178-2021 2014/07/29 [Refereed][Not invited]
     
    Objectives: To examine the relationship between level of insight and various subjective experiences for patients with schizophrenia. Materials and methods:Seventy-four patients with schizophrenia who were discharged from our hospital were evaluated. The level of insight into their illness and various subjective experiences were evaluated at discharge. We used the Scale to Assess Unawareness of Mental Disorder (SUMD) for evaluation of insight. In addition, five different rating scales were used to evaluate subjective experiences: Subjective Experience of Deficits in Schizophrenia (SEDS), Subjective Well-being under Neuroleptic drug treatment Short form (SWNS), Schizophrenia Quality of Life Scale (SQLS), Beck Depression Inventory (BDI), and the Drug Attitude Inventory (DAI)-30. Results: The SWNS and the scores for awareness of mental disorder and awareness of the social consequences of mental disorder on SUMD showed a weak positive correlation. The DAI-30 showed a significant negative correlation with most general items on SUMD and a negative correlation between the subscale scores for the awareness and attribution of past symptoms. SEDS, SWNS, SQLS, and the BDI significantly correlated with the subscale scores for awareness of current symptoms on SUMD, and weakly correlated with the subscale scores for attribution of current negative symptoms. Conclusion: Awareness of subjective distress was related to awareness of having a mental disorder. Feeling subjective distress was related to awareness of current symptoms, as well as to the ability to attribute current negative symptoms to a mental disorder. Positive attitudes toward medication correlated with better general insight into the illness. © 2014 Kako et al.
  • 統合失調症患者に対する認知矯正療法の効果 神経認知機能検査と事象関連電位の変化から
    井上 貴雄, 加藤 ちえ, 清水 祐輔, 豊巻 敦人, 橋本 直樹
    日本作業療法学会抄録集 (一社)日本作業療法士協会 48回 PMH - 17 1880-6635 2014/06
  • 私の診療経験から こころの応急対応(メンタルヘルス・ファーストエイド) 日常臨床場面における、うつ病の早期介入と自殺予防
    加藤 隆弘, 大塚 耕太郎, 鈴木 友理子, 藤澤 大介, 佐藤 玲子, 青山 久美, 橋本 直樹, 鈴木 志麻子, 神庭 重信
    臨牀と研究 大道学館出版部 91 (2) 289 - 294 0021-4965 2014/02 [Not refereed][Not invited]
  • Szuki Y, Kato A, Sato R, Fujisawa D, Aoyama K-Uehara, Hashimoto N, Yonemoto N, Fukasawa M, Otsuka K
    Eprdemiolgy and Psychiatric Sciences 23 167 - 176 2014 [Refereed][Not invited]
  • Naoki Hashimoto, Atsuhito Toyomaki, Masahiro Hirai, Tamaki Miyamoto, Hisashi Narita, Ryo Okubo, Ichiro Kusumi
    NEUROPSYCHIATRIC DISEASE AND TREATMENT 10 2221 - 2230 1178-2021 2014 [Refereed][Not invited]
     
    Background: Patients with schizophrenia show disturbances in both visual perception and social cognition. Perception of biological motion (BM) is a higher-level visual process, and is known to be associated with social cognition. BM induces activation in the "social brain network", including the superior temporal sulcus (STS). Although deficits in the detection of BM and atypical activation in the STS have been reported in patients with schizophrenia, it remains unclear whether other nodes of the "social brain network" are also atypical in patients with schizophrenia. Purpose: We aimed to explore whether brain regions other than STS were involved during BM perception in patients with schizophrenia, using functional magnetic resonance imaging (fMRI). Methods and patients: Seventeen patients with schizophrenia, and 17 age-and sex-matched healthy controls, underwent fMRI scanning during a one-back visual task, containing three experimental conditions: (1) BM, (2) scrambled motion (SM), and (3) static condition. We used one-sample t-tests to examine neural responses selective to BM versus SM within each group, and two-sample t-tests to directly compare neural patterns to BM versus SM in schizophrenics versus controls. Results: We found significant activation in the STS region when BM was contrasted with SM in both groups, with no significant difference between groups. On the contrary, significant activation in the medial prefrontal cortex (MPFC) and bilateral temporoparietal junction (TPJ) was found only in the control group. When we directly compared the two groups, the healthy controls showed significant greater activation in left MPFC and TPJ to BM versus SM than patients with schizophrenia. Conclusion: Our findings suggest that patients with schizophrenia show normal activation to biologically and socially relevant motion stimuli in the STS, but atypical activation in other regions of the social brain network, specifically MPFC and TPJ. Moreover, these results were not due to atypical processing of motion, suggesting that patients with schizophrenia lack in the recruitment of neural circuits needed for the visual perception of social cognition.
  • Yuki Kako, Koki Ito, Naoki Hashimoto, Kuniyoshi Toyoshima, Yusuke Shimizu, Nobuyuki Mitsui, Yutaka Fujii, Teruaki Tanaka, Chiro Kusumi
    NEUROPSYCHIATRIC DISEASE AND TREATMENT 10 1415 - 1422 1178-2021 2014 [Refereed][Not invited]
     
    Objectives: To examine the relationship between level of insight and various subjective experiences for patients with schizophrenia. Materials and methods: Seventy-four patients with schizophrenia who were discharged from our hospital were evaluated. The level of insight into their illness and various subjective experiences were evaluated at discharge. We used the Scale to Assess Unawareness of Mental Disorder (SUMD) for evaluation of insight. In addition, five different rating scales were used to evaluate subjective experiences: Subjective Experience of Deficits in Schizophrenia (SEDS), Subjective Well-being under Neuroleptic drug treatment Short form (SWNS), Schizophrenia Quality of Life Scale (SQLS), Beck Depression Inventory (BDI), and the Drug Attitude Inventory (DAI)-30. Results: The SWNS and the scores for awareness of mental disorder and awareness of the social consequences of mental disorder on SUMD showed a weak positive correlation. The DAI-30 showed a significant negative correlation with most general items on SUMD and a negative correlation between the subscale scores for the awareness and attribution of past symptoms. SEDS, SWNS, SQLS, and the BDI significantly correlated with the subscale scores for awareness of current symptoms on SUMD, and weakly correlated with the subscale scores for attribution of current negative symptoms. Conclusion: Awareness of subjective distress was related to awareness of having a mental disorder. Feeling subjective distress was related to awareness of current symptoms, as well as to the ability to attribute current negative symptoms to a mental disorder. Positive attitudes toward medication correlated with better general insight into the illness.
  • Yusuke Shimizu, Nobuki Kitagawa, Nobuyuki Mitsui, Yutaka Fujii, Atsuhito Toyomaki, Naoki Hashimoto, Yuki Kako, Teruaki Tanaka, Satoshi Asakura, Ichiro Kusumi
    Psychiatry Research 210 (3) 913 - 918 0165-1781 2013/12/30 [Refereed][Not invited]
     
    Quality of life (QOL) has been reported to be impaired in patients with major depressive disorder (MDD), even after remission according to symptom rating scales. Although a relationship between QOL and neurocognitive dysfunction has been reported during depressive episodes, little is known about this relationship in remitted MDD patients. The aim of the present study was to investigate the relationship between QOL and neurocognitive dysfunction in patients with remitted MDD while controlling for confounding factors. Forty-three remitted MDD patients were assessed with neuropsychological tests and QOL, which was measured by a short-form 36-item health survey. The neurocognitive performances of the patients were compared with those of 43 healthy controls. We next evaluated the relationships between neurocognitive impairments, clinical factors, and QOL. Remitted MDD patients had poorer neurocognitive performances than healthy controls for psychomotor speed, attention, and verbal memory. Residual depressive symptoms were strongly associated with QOL. Delayed verbal recall was associated with general health perceptions, which are part of the QOL assessment, even after the effects of the residual depressive symptoms were considered. The results may indicate that clinicians should try to detect neurocognitive dysfunctions that may interfere with QOL using neurocognitive assessments in their daily practice. © 2013 Elsevier Ireland Ltd.
  • 北海道におけるat risk mental state患者の受診経路に関する多施設調査
    大久保 亮, 橋本 直樹, 伊藤 かほり, 白坂 知彦, 日下 直文, 館農 勝, 久住 一郎
    精神神経学雑誌 (公社)日本精神神経学会 115 (10) 1090 - 1090 0033-2658 2013/10
  • Effectiveness of brief suicide management training program for medical residents in Japan: A cluster randomized controlled trial
    Suzuki Y, Kato TA, Sato R, Fujisawa D, Aoyama-Uehara K, Hashimoto N, Yonemoto N, Fukasawa M, Otsuka K
    Epidemiology and Psychiatric Sciences 1 - 10 2013/07 [Refereed][Not invited]
  • 統合失調症患者に対する認知矯正療法の効果 神経認知機能とThe Schizophrenia Quality of Life Scale日本語版(JSQLS)の変化から
    井上 貴雄, 加藤 ちえ, 宮島 真貴, 豊巻 敦人, 橋本 直樹
    日本作業療法学会抄録集 (一社)日本作業療法士協会 47回 O202 - O202 1880-6635 2013/06
  • Otsuka K, Suzuki Y, Fujisawa D, Kato TA, Sato R, Aoyama-Uehara K, Hashimoto N, Suzuki S, Kurosawa M
    Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 日本精神神経学会 115 (7) 792 - 796 0033-2658 2013 [Refereed][Not invited]
  • 北海道におけるat risk mental state患者の受診経路に関する多施設調査
    大久保 亮, 橋本 直樹, 伊藤 かほり, 大宮 友貴, 中右 麻理子, 馬場 俊明, 白坂 知彦, 小林 清樹, 立花 蘭, 館農 勝, 久住 一郎
    精神神経学雑誌 (公社)日本精神神経学会 (2012特別) S - 412 0033-2658 2012/05
  • 気分安定化薬が無効でaripiprazoleへの主剤切り替えが奏効した難治性双極性障害の1例
    渡辺 晋也, 橋本 直樹, 久住 一郎, 岩田 愛雄, 朴 秀賢, 伊藤 侯輝, 小山 司
    精神神経学雑誌 (公社)日本精神神経学会 114 (1) 65 - 65 0033-2658 2012/01 [Not refereed][Not invited]
  • 気分障害における作業記憶課題遂行時の事象関連電位・事象関連同期の異常
    豊巻 敦人, 清水 祐輔, 橋本 直樹, 宮島 真貴, 久住 一郎, 小山 司
    臨床神経生理学 (一社)日本臨床神経生理学会 39 (5) 486 - 486 1345-7101 2011/10 [Not refereed][Not invited]
  • S. Onodera, H. Aoyama, N. Hashimoto, A. Toyomaki, N. Nishikawa, K. K. Tha, K. Ogisu, S. Terae, H. Shirato
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 78 (3) S293 - S293 0360-3016 2010 [Refereed][Not invited]
  • 精神科医療における非自発的治療および行動制限について若手の視点で考える 急性期統合失調症に対する初期治療と行動制限について 若手精神科医を対象とした意識調査から
    館農 勝, 杉浦 寛奈, 上原 久美, 橋本 直樹, 藤澤 大介, 高橋 英彦, 趙 岳人, 佐藤 創一郎
    精神神経学雑誌 (公社)日本精神神経学会 (2009特別) S - 351 0033-2658 2009/05
  • 第二世代抗精神病薬服用中の統合失調症患者における血糖モニタリングガイダンスの実際 ベースライン調査から
    久住 一郎, 橋本 直樹, 伊藤 侯輝, 小山 司
    精神神経学雑誌 (公社)日本精神神経学会 (2009特別) S - 247 0033-2658 2009/05 [Not refereed][Not invited]
  • Japan Young Psychiatrists Organization: Promoting Professional Development and Networking for the future of psychiatry
    Uehara K, Baba T, Hashimoto N, Matsumoto R, Sugiura K, Tanaka T, Wake Y, Fujisawa D
    Asia Pacific Psychiatry 1 48 - 50 2009 [Not refereed][Invited]
  • 薬の使い方シリーズ Quetiapineを使いこなす 薬剤選択
    久住 一郎, 橋本 直樹, 伊藤 侯輝, 小山 司
    臨床精神薬理 (株)星和書店 11 (9) 1749 - 1753 1343-3474 2008/09 [Not refereed][Not invited]
  • Pathway to Psychiatric Care in Japan: a multicenter observational study.
    Fujisawa Daisuke, Hashimoto N, Masamune-Koizumi Y, Otsuka K, Tateno M, Okugawa G, Nakagawa A, Sato R, Kikuchi T, Tonai E, Yoshida K, Mori T, Takahashi H, Sato S, Igimi H, Waseda Y, Ueno T, Morokuma I, Takahashi K, Sartorius N
    Int J Mental Health Systems 9 (14) 2008 [Refereed][Not invited]
  • 統合失調症急性期症例におけるolanzapine口腔内崩壊錠の使用経験?多施設共同研究の結果からー
    伊藤耕一, 久住一郎, 上村恵一, 岡崎大介, 塚本典子, 藤井 泰, 武重宏呂修, 千秋 勉, 三枝英之, 池田輝明, 本田 稔, 関口奈緒, 新出泰士, 坂井陽子, 臼窪幸恵, 栃木昭彦, 甲野智也, 橋本直樹, 白木淳子, 掛川優紀子, 臼居礼子, 細川嘉之, 松山哲晃, 伊藤侯輝, 小山 司
    精神科治療学 23 613 - 622 2008 [Refereed][Not invited]
  • 日本若手精神科医の会JYPOによる精神科受診経路に関する多施設研究Pathway to psychiatric care in Japan身体科医による精神科疾患の病名説明と精神科受診の遅れとの関係について
    小泉 弥生, 五十君 啓泰, 上原 久美, 大塚 耕太郎, 奥川 学, 菊地 俊暁, 清原 義明, 佐渡 充洋, 佐藤 玲子, 佐藤 創一郎, 高橋 克昌, 高橋 英彦, 館農 勝, 藤内 栄太, 橋本 直樹, 吹田 恭子, 藤澤 大介, 松岡 弘修, 諸隈 一平, 吉岡 知子
    精神神経学雑誌 (公社)日本精神神経学会 (2007特別) S256 - S256 0033-2658 2007/05
  • 修正型電気けいれん療法(mECT)施行時に使用した筋弛緩薬サクシニルコリンによる悪性高熱症が疑われた統合失調症の1例
    古堅 祐行, 伊藤 侯輝, 橋本 直樹, 松山 哲晃, 村下 真理, 安部川 智浩, 久住 一郎, 小山 司
    精神神経学雑誌 (公社)日本精神神経学会 109 (5) 498 - 498 0033-2658 2007/05 [Not refereed][Not invited]
  • 日本若手精神科医の会JYPOによる精神科受診経路に関する多施設研究Pathway to psychiatric care in Japan 精神科疾患の病名告知について
    小泉 弥生, 五十君 啓泰, 上原 久美, 大塚 耕太郎, 奥川 学, 菊地 俊暁, 清原 義明, 佐渡 充洋, 佐藤 玲子, 佐藤 創一郎, 高橋 克昌, 高橋 英彦, 館農 勝, 藤内 栄太, 橋本 直樹, 吹田 恭子, 藤澤 大介, 松岡 弘修, 諸隈 一平, 吉岡 知子
    精神神経学雑誌 (公社)日本精神神経学会 (2006特別) S263 - S263 0033-2658 2006/05
  • 若手精神科医の立場から精神医療を考える 精神医療の現状と地域の抱える課題 東北・北海道の地域精神医療の課題と試み
    今村 弥生, 石井 貴男, 今井 智之, 菊地 紗耶, 橋本 直樹
    精神神経学雑誌 (公社)日本精神神経学会 (2006特別) S318 - S318 0033-2658 2006/05
  • Imamura Y, Ishii T, Imai T, Kikuchi S, Hashimoto N
    Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 9 108 (9) 957 - 960 0033-2658 2006 [Refereed][Not invited]

MISC

  • 精神医学のフロンティア 統合失調症患者における認知機能障害の推定 多施設共同研究
    藤野 陽生, 住吉 チカ, 安田 由華, 山森 英長, 藤本 美智子, 福永 雅喜, 三浦 健一郎, 竹林 佑人, 岡田 直大, 磯村 周一, 河野 直子, 豊巻 敦人, 久我 弘典, 磯部 昌憲, 大矢 一登, 岡久 祐子, 高木 学, 橋本 直樹, 加藤 正樹, 鬼塚 俊明, 上野 雄文, 大沼 徹, 笠井 清登, 尾崎 紀夫, 住吉 太幹, 井村 修, 橋本 亮太, COCORO  精神神経学雑誌  120-  (4)  255  -261  2018/04  [Not refereed][Not invited]
     
    統合失調症患者では,個々の患者で程度はさまざまであるものの,認知機能の低下が生じることが報告されてきた.本研究の目的は,統合失調症患者の病前知能と現在の知的機能から推定された認知機能障害の程度を調査することである.11の大学病院などからリクルートされた,446名の統合失調症患者と686名の健常者に日本版WAIS-III成人知能検査,知的機能の簡易評価(JART)の25項目短縮版を実施し,現在の知的能力と病前推定知能を評価した.現在の知的能力と病前推定知能の差から認知機能障害スコアを算出した.統合失調症患者での推定認知機能障害スコアは-16.3,現在の知的機能が84.2,病前推定知能は100.5であり,いずれの項目においても,健常者と比較して有意に低かった.さらに,推定認知機能障害スコアで20以上の低下を示した患者の割合は39.7%であった.推定認知機能障害スコアを用いると,81.6%の患者と健常者を正しく判別することができた.本研究によって,統合失調症患者の認知機能障害の程度とその分布が明らかとなった.このような知見は,認知機能障害をもつ患者を同定し,認知機能障害の重症度の評価をするうえで寄与しうるものである.(著者抄録)
  • 岡 松彦, 大宮 友貴, 橋本 直樹, 久住 一郎  精神医学  59-  (10)  937  -941  2017/10  [Not refereed][Not invited]
     
    抗精神病薬に多い副作用の一つとして体重増加があるが,aripiprazole(APZ)は体重増加を来しにくいとされている。症例は25歳男性,統合失調症。22歳時に幻覚妄想状態で発症し,25歳時に入院。入院後blonanserinやhaloperidol(HPD)で加療されたが,症状改善に乏しく,APZへ切り替えて退院となった。一方,APZへ変更後は食餌療法や運動療法の導入にもかかわらず4週で約7kg,半年で約15kg,1年半で約30kgの著明な体重増加を来した。後に主剤をAPZからHPDへ戻したが,減量は困難であった。急速な体重増加の事前の予測は困難であり,また後に減量が困難となり得ることから,体重増加を認めた際には薬剤の切り替えを検討すべきであると考えられた。(著者抄録)
  • EGUIDE講習会の効果測定 筑波大学精神神経科グループにおける基礎調査
    根本 清貴, 翠川 晴彦, 星野 直美, 関根 彩, 山本 智也, 橋本 直樹, 渡邊 衡一郎, 稲田 健, 橋本 亮太, 新井 哲明  日本生物学的精神医学会・日本神経精神薬理学会合同年会プログラム・抄録集  39回・47回-  165  -165  2017/09  [Not refereed][Not invited]
  • 精神科医療の普及と教育に対するガイドラインの効果に関する研究 北海道地区、うつ病講習についての報告
    澤頭 亮, 橋本 直樹, 山本 智也, 稲田 健, 渡邊 衡一郎, 橋本 亮太, 久住 一郎  日本うつ病学会総会・日本認知療法・認知行動療法学会プログラム・抄録集  14回・17回-  247  -247  2017/07  [Not refereed][Not invited]
  • 精神科研修医における燃え尽き症候群についての国際共同研究(BoSS International) 日本国内調査(BoSS Japan)の結果から
    館農 勝, 加藤 隆弘, 青山 久美, 中野 和歌子, 中前 貴, 内田 直樹, 橋本 直樹, 菊地 紗耶, 和気 洋介, 藤澤 大介, 猪狩 圭介, 大塚 耕太郎, 高橋 克昌, 奥川 学, 渡辺 範雄, 白坂 知彦, Jovanovic Nikolina, Beezhold Julian  精神神経学雑誌  119-  (2)  83  -97  2017/02  [Not refereed][Not invited]
     
    【背景】燃え尽き症候群は,仕事上のストレスに曝された結果生じる心理的反応である.医師で発生率が高いとされるが,とりわけ,臨床経験が少ない研修医はリスクが高い.今回,精神科研修医の燃え尽き症候群に関する国際調査(BoSS)の日本データを解析し報告する.【方法】BoSSは欧州精神科研修医連合(EFPT)により企画され,欧州を中心に22の国・地域が参加した.各国の研究責任者が協力者を募り,その所属先に勤務する精神科研修医の同意を得た上で,メールアドレスのリストを作成し調査対象とした.データ収集は全てオンライン上で,匿名で行った.【結果】7,525名のうち1,980名が回答を完了し(回答率26.0%),日本からは95名(同41.5%)分のデータが得られた.平均31.8±4.8歳で,臨床経験は3.6±2.5年,男性が67.4%であった.勤務時間は72.3±27.1時間/週と参加国中最長で,指導医に相談する機会は2.9±4.4時間のみであった.Maslach Burnout Inventory(MBI)を用いて評価した結果,重度の燃え尽き症候群と定義した,疲弊感2.20以上,かつ,シニシズム2.00以上の者は42.0%であった.燃え尽き症候群の有無で比較したところ,ある群(n=41)では,うつ傾向を評価するPHQ-9スコアの高さと,指導医への相談時間の短さで有意差を認めた.【考察】全体データの解析では,若年者,長時間の勤務,指導医との相談機会の不足,一定勤務時間ごとの休憩の欠如などで,燃え尽き症候群との関連性が認められた.日本のデータでも,同様の傾向を認めた.研修医の燃え尽きは,研修からの脱落や医療事故の原因になる重要な問題である.研修医は燃え尽きリスクが高いことを認識し,指導医から声をかける機会を増やすことが予防につながる可能性が考えられた.(著者抄録)
  • Levetiracetamの急激な中止により引き起こされた一過性脳梁膨大部病変の一例
    澤頭 亮, 成田 尚, 橋本 直樹, 栗田 紹子, 中川 伸, 久住 一郎  日本神経精神薬理学会年会プログラム・抄録集  46回-  163  -163  2016/07  [Not refereed][Not invited]
  • ENIGMA-SZJ:統合失調症の皮質下体積のメタアナリシス
    岡田 直大, 福永 雅喜, 山下 典生, 越山 太輔, 山森 英長, 大井 一高, 安田 由華, 藤本 美智子, 渡邉 嘉之, 八幡 憲明, 根本 清貴, 磯部 昌憲, 磯村 周一, 夏堀 龍暢, 成田 尚, 橋本 直樹, 宮田 淳, 小池 進介, 高橋 努, 山末 英典, 松尾 幸治, 鬼塚 俊明, 飯高 哲也, 吉村 玲児, 渡邉 義文, 鈴木 道雄, 武田 雅俊, 尾崎 紀夫, 笠井 清登, 橋本 亮太  日本生物学的精神医学会・日本神経精神薬理学会合同年会プログラム・抄録集  37回・45回-  204  -204  2015/09  [Not refereed][Not invited]
  • Aripiprazoleにより著明な体重増加を来した症例の検討 ケースシリーズ
    岡 松彦, 大宮 友貴, 橋本 直樹, 荒井 勇輝, 三井 信幸  精神神経学雑誌  116-  (12)  1040  -1040  2014/12  [Not refereed][Not invited]
  • 北海道大学病院精神科神経科デイケアクリニカルパス(第二報) 運用8ヵ月における成果とその検討
    成田 学, 賀古 勇輝, 栗田 紹子, 橋本 直樹, 秋谷 絵理, 平松 ふみ子, 斉藤 かおり, 照井 涼子, 石塚 麻伊子, 藤田 真善美, 久住 一郎  精神神経学雑誌  116-  (12)  1042  -1042  2014/12  [Not refereed][Not invited]
  • Akane Miyazaki, Atsuhito Toyomaki, Naoki Hashimoto, Ichiro Kusumi  INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY  94-  (2)  236  -237  2014/11  [Not refereed][Not invited]
  • 若槻 百美, 鈴木 克治, 仲唐 安哉, 橋本 直樹, 中川 伸, 井上 猛, 久住 一郎, 小山 司  精神医学  56-  (11)  951  -957  2014/11  [Not refereed][Not invited]
     
    Akiskalらは気質を定量化する目的で自記式質問紙であるTEMPS-A(Temperament Evaluation of Memphis,Pisa,Paris and San Diego-autoquestionnaire version)を作成した。我々はTEMPS-A短縮版で測定される気質と入院大うつ病性障害症例(MDD)の転帰との関連を検討した。2007年4月から2008年3月に当科入院し入院時にMDDと診断された症例のうち,2009年7月時点で診断が気分障害圏である23例を対象とし,診療録を用いた後方視的研究を行い,TEMPS-A短縮版の記載を依頼した。平均観察期間1年10ヵ月で22%が双極性障害(BP)に診断が変更され,BP群は循環気質の点数がMDD群と比して有意に高かった。循環気質の高得点群では,寛解率が低く,抗うつ薬内服中の躁転が多く,抗うつ薬のwear-offが少なかった。気分障害診療における気質の把握の有用性および,TEMPS-A短縮版で検出される循環気質が双極性障害の予測因子となる可能性が示唆される。(著者抄録)
  • 草地麻実, 大久保亮, 納谷昌直, 成田尚, 橋本直樹, 久住一郎  精神神経学雑誌  116-  (6)  526  2014/06/25  [Not refereed][Not invited]
  • 統合失調症患者の病識と治療転帰との関連についての検討
    賀古 勇輝, 橋本 直樹, 久住 一郎  精神神経学雑誌  (2014特別)  S617  -S617  2014/06  [Not refereed][Not invited]
  • 橋本 直樹, 豊巻 敦人, 久住 一郎  精神科  24-  (4)  403  -407  2014/04
  • 大久保亮, 草地麻実, 納谷昌直, 成田尚, 橋本直樹, 久住一郎  統合失調症研究  4-  (1)  95  2014/03  [Not refereed][Not invited]
  • 北海道大学職員を対象とした、メンタルヘルスファーストエイドを用いたゲートキーパー養成研修の効果に関する研究 大学生自殺者の減少を目指して
    橋本 直樹, 朝倉 聡, 斉藤 美香, 久蔵 孝幸, 大崎 明美, 武田 弘子, 川島 るい  精神神経学雑誌  115-  (11)  1160  -1160  2013/11  [Not refereed][Not invited]
  • うつに対する幼少期ストレス、気質、ライフイベントの影響
    中井 幸衛, 井上 猛, 戸田 裕之, 豊巻 敦人, 中川 伸, 北市 雄士, 仲唐 安哉, 谷知 正章, 林下 善行, 三井 信幸, 橋本 直樹, 久住 一郎  精神神経学雑誌  115-  (11)  1159  -1159  2013/11  [Not refereed][Not invited]
  • 気分障害の難治化と養育環境、気質、ストレスの関係
    戸田 裕之, 井上 猛, 角田 智哉, 谷知 正章, 田中 徹平, 中川 伸, 北市 雄士, 橋本 直樹, 中井 幸衛, 吉野 相英, 野村 総一郎  精神神経学雑誌  (2013特別)  S  -540  2013/05  [Not refereed][Not invited]
  • 統合失調症患者に対する認知リハビリテーション(ブレインステーション)についての報告 北海道大学病院精神科神経科の取り組み
    井上 貴雄, 橋本 直樹, 豊巻 敦人, 加藤 ちえ, 岸 展江, 國田 幸治, 中谷 紫乃, 川島 るい, 佐藤 昭宏, 成田 学, 松尾 萌, 宮島 真貴, 清水 祐輔, 久住 一郎  精神神経学雑誌  115-  (1)  101  -101  2013/01  [Not refereed][Not invited]
  • 久住 一郎, 伊藤 候輝, 本田 稔, 林下 忠行, 上村 恵一, 橋本 直樹, 村崎 光邦, 渥美 義仁, 門脇 孝, 小山 司  精神神經學雜誌 = Psychiatria et neurologia Japonica  114-  (8)  881  -885  2012/08/25
  • 初期臨床研修医における、患者の自殺行動への対処スキル
    藤澤 大介, 鈴木 友理子, 加藤 隆弘, 橋本 直樹, 佐藤 玲子, 上原 久美, 深澤 舞子, 冨田 真幸, 渡邊 衡一郎, 鹿島 晴雄, 大塚 耕太郎  精神神経学雑誌  (2011特別)  S  -217  2011/10  [Not refereed][Not invited]
  • 若槻百美, 仲唐安哉, 鈴木克治, 橋本直樹, 中川伸, 井上猛, 久住一郎, 小山司  Bipolar Disord  9-  74-76  -76  2011/05/20  [Not refereed][Not invited]
  • 賀古 勇輝, 藤井 泰, 橋本 直樹  Japanese journal of clinical psychiatry  39-  (10)  1347  -1354  2010/10  [Not refereed][Not invited]
     
    全身性エリテマトーデス(SLE)に随伴した精神症状や認知機能障害の治療経過中、認知機能検査を施行し、治療法選択や効果判定の指標として有効であった2症例(21歳女、22歳女)について報告した。2例とも免疫学的指標や脳画像検査においてSLEの増悪を示唆する所見に乏しかったが、認知機能検査では実効機能や運動速度、注意機能など複数の認知領域で顕著な異常が認められた。ステロイドパルス療法およびバルプロ酸投与により精神症状や認知機能の改善を認め、その後施行した認知機能検査では改善が認められ、認知機能障害の改善を客観的に確認することができた。
  • 第二世代抗精神病薬服用中の統合失調症患者における血糖モニタリングガイダンスの実際 1年後調査から
    久住 一郎, 伊藤 侯輝, 橋本 直樹, 賀古 勇輝, 小山 司  日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集  20回・40回-  140  -140  2010/09  [Not refereed][Not invited]
  • 精神科的早期介入と偏見除去のための臨床研修医への短期教育法の効果に関するパイロット研究
    橋本 直樹, 鈴木 友理子, 加藤 隆弘, 佐藤 玲子, 藤澤 大介, 上原 久美, 神庭 重信, 大塚 耕太郎  日本社会精神医学会雑誌  19-  (1)  121  -122  2010/07  [Not refereed][Not invited]
  • 若手精神科医における燃え尽き症候群に関する国際共同研究 日本国内調査(BoSS Japan)中間報告
    館農 勝, 加藤 隆弘, 上原 久美, 中野 和歌子, 中前 貴, 内田 直樹, 橋本 直樹, 菊地 紗耶, 和気 洋介, 藤沢 大介, 猪狩 圭介, 大塚 耕太郎, 高橋 克昌, 奥川 学, 渡辺 範雄, 白坂 知彦  精神神経学雑誌  (2010特別)  S  -210  2010/05  [Not refereed][Not invited]
  • 入院うつ病症例の気質と診断変遷の関連
    若槻 百美, 仲唐 安哉, 鈴木 克治, 橋本 直樹, 中川 伸, 井上 猛, 久住 一郎, 小山 司  精神神経学雑誌  (2010特別)  S  -197  2010/05  [Not refereed][Not invited]
  • Mie Matsui, Naoki Hashimoto, Atsushi Toyomaki, Ichiro Kusumi, Tsukasa Koyama  SCHIZOPHRENIA RESEARCH  117-  (2-3)  326  -326  2010/04  [Not refereed][Not invited]
  • 入院うつ病症例のbipolarityに着目した治療と予後 循環気質との関連
    若槻 百美, 仲唐 安哉, 鈴木 克治, 橋本 直樹, 中川 伸, 井上 猛, 久住 一郎, 小山 司  精神神経学雑誌  112-  (4)  413  -413  2010/04  [Not refereed][Not invited]
  • 社交不安/対人恐怖評価尺度(Social Anxiety/Taijin-kyofu Scale:SATS)
    朝倉 聡, 井上 猛, 長谷川 典, 北川 信樹, 藤井 泰, 賀古 勇輝, 仲唐 安哉, 橋本 直樹, 伊藤 侯輝, 田中 輝明, 中川 伸, 久住 一郎, 小山 司  不安障害研究  2-  (1)  164  -164  2010/03  [Not refereed][Not invited]
  • 橋本 直樹, JY, O行動制限班  精神神經學雜誌 = Psychiatria et neurologia Japonica  112-  (1)  43  -48  2010/01/25  [Not refereed][Not invited]
  • 東北地方の精神科医の勤務実態調査報告
    菊地 紗耶, 正宗 弥生, 橋本 直樹, 上原 久美, 加藤 隆弘, 吹田 恭子, 藤本 美智子, 安保 英勇, 松岡 洋夫  精神神経学雑誌  111-  (6)  706  -706  2009/06  [Not refereed][Not invited]
  • 臨床研修医を対象とした、自殺対応スキルおよび偏見除去に関する研修法の効果に関するパイロット研究
    鈴木 友理子, 加藤 隆弘, 佐藤 玲子, 藤澤 大介, 上原 久美, 橋本 直樹, 神庭 重信, 大塚 耕太郎  精神神経学雑誌  (2009特別)  S  -310  2009/05  [Not refereed][Not invited]
  • 上原 久美, 加藤 隆弘, 橋本 直樹, 和気 洋介, 田中 徹平, 馬場 俊明, 藤澤 大介  精神神經學雜誌 = Psychiatria et neurologia Japonica  111-  (2)  221  -226  2009/02/25  [Not refereed][Not invited]
  • 青木 信生, 松本 良平, 長峯 正典, 鈴木 友理子, 和気 洋介, 橋本 直樹  精神神經學雜誌 = Psychiatria et neurologia Japonica  110-  (12)  1145  -1147  2008/12/25  [Not refereed][Not invited]
  • 菊地 紗耶, 上原 久美, 橋本 直樹, 小泉 弥生, 吉岡 知子, 杉浦 寛奈, 松岡 洋夫  精神神經學雜誌 = Psychiatria et neurologia Japonica  110-  (7)  563  -570  2008/07/25  [Not refereed][Not invited]
  • 精神科医療に関する意識の変化 神奈川県精神医学会会員102人の意識調査から
    上原 久美, 杉浦 寛奈, 鎌田 鮎子, 辛島 文, 小西 潤, 近藤 大三, 福島 浩, 堀 岳人, 山本 めぐみ, 橋本 直樹, 加藤 隆弘, 藤澤 大介, 小田原 俊成, 平安 良雄  精神神経学雑誌  110-  (4)  338  -339  2008/04  [Not refereed][Not invited]
  • 橋本 直樹, 杉浦 寛奈, 長峯 正典, 佐藤 玲子, 和気 洋介, 加藤 隆弘, 鈴木 友理子, 藤澤 大介, 佐藤 創一郎, 上原 久美  精神神經學雜誌 = Psychiatria et neurologia Japonica  110-  (3)  175  -177  2008/03/25
  • 若手精神科医の育成と研修環境 神奈川県精神医学会会員を対象とした意識調査から
    上原 久美, 杉浦 寛奈, 鎌田 鮎子, 辛島 文, 小西 潤, 近藤 大三, 福島 浩, 堀 岳人, 山本 めぐみ, 藤澤 大介, 橋本 直樹, 加藤 隆弘  神奈川県精神医学会誌  (57)  75  -81  2008/03  [Not refereed][Not invited]
     
    神奈川県精神医学会会員を対象に、若手医師の育成と研修環境についての意識調査を実施し、102名から有効回答を得た。その結果、勤務先ごとの興味ある分野の調査については、大学や総合病院では薬理学的な興味が、クリニックや精神科単科病院では精神病理への興味が高く、職場によって重視する内容が異なる傾向がみられた。卒後20年以内の精神科医の約7割が精神科医となって3年以内に大学病院での勤務を経験していた。大学病院の医局のどのようなところを評価するかという質問に対し、1年目は研修を一番に挙げているが、2〜10年目は医局員同士の交流を挙げており、大学病院の医局が、研修そのものだけでなく、精神科医同士の相互交流にも貢献していることが示唆された。
  • 加藤 隆弘, 橋本 直樹, 佐藤 玲子, 小泉 弥生, 中川 敦夫, 藤澤 大介, 上原 久美  精神神經學雜誌 = Psychiatria et neurologia Japonica  109-  (11)  1045  -1049  2007/11/25  [Not refereed][Not invited]
  • 和気 洋介, 佐藤 創一郎, 橋本 直樹, 加藤 隆弘, 馬場 俊明, 内田 直樹, 澤田 健, 小泉 弥生, 中川 敦夫, 館農 勝, 上原 久美  精神神經學雜誌 = Psychiatria et neurologia Japonica  109-  (10)  921  -924  2007/10/25  [Not refereed][Not invited]
  • 橋本 直樹, 豊巻 敦人, 久住 一郎  Psychiatry  10-  (6)  496  -499  2007/06
  • 藤沢 大介, 橋本 直樹, 小泉 弥生, 大塚 耕太郎, 奥川 学, 館農 勝, 五十君 啓泰, 上野 雄文, 菊地 俊暁, 佐藤 創一郎, 佐藤 玲子, 高橋 克昌, 高橋 英彦, 中川 敦夫, 藤内 栄太, 森 貴俊, 諸隈 一平, 吉田 公輔, 早稲田 芳史, 日本若手精神科医の会(JYPO)PATHWAY研究グループ  精神医学  49-  (1)  7  -15  2007/01  [Not refereed][Not invited]
     
    全国13施設が参加して精神科受診経路に関する多施設共同研究を実施した。精神科を初診した患者84名を対象に、受診経路、受診の遅れ、精神科受診前の処遇内容について調査した。対象のうち直接精神科を受診した症例は39.3%で、それ以外は総合病院の一般精神科からの紹介や一般身体科の開業医からの紹介が主たる受診経路であった。受診経路の90%は医療機関からであった。受診の遅れは、主訴発生から3〜8.5週であった。各経路ごとの受診の遅れの違いについても調査した。受診の遅れを招く背景として、一般住民の精神疾患についての知識の普及が不十分なこと、精神科受診に対する抵抗感があった。一般身体科医師による病名告知、初期治療は、不十分な場合が多かった。
  • TOYOMAKI Atsuhito, Hashimoto Naoki, TAKAHASHI Yui, MIYAMOTO Tamaki, KUSUMI Ichiro, HIRAI Masahiro, KOYAMA Tsukasa  Journal of Life Support Engineering  19-  (0)  36  -36  2007  [Not refereed][Not invited]
  • 神奈川県における卒後研修に関する意識調査
    上原 久美, 杉浦 寛奈, 鎌田 鮎子, 辛島 文, 小西 潤, 近藤 大三, 福島 浩, 堀 岳人, 山本 めぐみ, 橋本 直樹, 加藤 隆弘, 日本若手精神科医の会, 卒後教育研究班  神奈川県精神医学会誌  (56)  92  -93  2006/12  [Not refereed][Not invited]
  • 今村 弥生, 石井 貴男, 今井 智之, 菊地 紗耶, 橋本 直樹  精神神經學雜誌 = Psychiatria et neurologia Japonica  108-  (9)  957  -960  2006/09/25  [Not refereed][Not invited]
  • うつ病患者における海馬体積とデキサメタゾン-CRH負荷テストとの関連
    松山 哲晃, 中川 伸, 橋本 直樹, 久住 一郎, 寺江 聡, 小山 司  神経化学  45-  (2-3)  385  -385  2006/08  [Not refereed][Not invited]
  • 精神科受診経路に関する多施設研究(PATHWAY研究)(第3報) 身体科医療機関での治療についての満足度調査
    橋本 直樹, 藤澤 大介, 大塚 耕太郎, 小泉 弥生, 山之内 芳雄, 森 貴俊, 加藤 隆弘, 吹田 恭子, 館農 勝, 今村 弥生, 菊地 紗耶, 吉岡 知子, 佐藤 創一郎  精神神経学雑誌  (2006特別)  S350  -S350  2006/05  [Not refereed][Not invited]
  • 橋本 直樹, 藤澤 大介, 大塚 耕太郎, 小泉 弥生, 佐藤 創一郎, 館農 勝, 吹田 恭子, 古岡 知子, 早稲田 芳史, 奥川 学, 佐渡 充洋, 高橋 克昌, 今村 弥生, 村岡 弘修, 清原 義明, 上原 久美, 菊地 俊暁, 佐藤 玲子, 高橋 英彦, 諸隈 一平  精神神経学雑誌  108-  (2)  201  -201  2006/02  [Not refereed][Not invited]
  • 橋本直樹, 藤澤大介, 大塚耕太郎, 小泉弥生  精神医学  48-  1276  -1285  2006  [Not refereed][Not invited]
  • 橋本 直樹, 中島 幸治, 朝倉 聡, 北川 信樹, 井上 猛, 小山 司  精神医学  47-  (10)  1137  -1142  2005/10  [Not refereed][Not invited]
     
    SSRI,SNRI導入後の うつ病治療における第一選択薬の変化,SSRIとSNRIの効果についての長期的転帰による評価,SSRI,SNRIと従来薬での副作用に対する治療薬の変化について当科の状況を調査した.その結果,当科においてはmilnacipran,SSRIsが第一選択薬として確実に浸透していることが明らかとなった.中でもmilnacipranは第一選択薬として最も多く選択されており,従来の薬剤と比較して治療効果に遜色がないこと,副作用が少ないことなどが理由として考えられた
  • 精神科受診経路に関する多施設研究 Pathway to psychiatric care in Japan
    藤澤 大介, 早稲田 芳史, 上原 久美, 大塚 耕太郎, 奥川 学, 菊地 俊暁, 小泉 弥生, 佐渡 充洋, 佐藤 玲子, 佐藤 創一郎, 高橋 克昌, 高橋 英彦, 館農 勝, 今村 弥生, 橋本 直樹, 吹田 恭子, 松岡 弘修, 諸隈 一平, 吉岡 知子, 清原 義明  精神神経学雑誌  (2005特別)  S280  -S280  2005/05  [Not refereed][Not invited]
  • 地域精神医療ネットワーク 宗谷地域における市立稚内病院精神神経科の役割
    中島 幸治, 坂井 陽子, 岩田 和也, 千秋 勉, 橋本 直樹, 朝倉 聡, 小山 司  精神神経学雑誌  106-  (11)  1519  -1520  2004/11  [Not refereed][Not invited]
  • 藤澤 大介, 佐藤 玲子, 高橋 克昌, 小泉 弥生, 橋本 直樹, 五十君 啓泰, 上野 雄文, 大塚 耕太郎, 奥川 学, 菊地 俊暁, 佐藤 創一郎, 高橋 英彦, 館農 勝, 中川 敦夫, 藤内 栄太, 森 貴俊, 諸隈 一平, 吉田 公輔, 早稲田 芳史  精神神経学雑誌  106-  (11)  1510  -1510  2004/11  [Not refereed][Not invited]
  • 精神科受診経路に関する多施設研究Path way to Psychiatric Care in Japan パイロットスタディー
    橋本 直樹, 藤沢 大介, 佐藤 玲子, 高橋 克昌, 小泉 弥生, 五十君 啓泰, 上野 雄文, 大塚 耕太郎, 奥川 学, 菊地 俊暁, 佐藤 創一郎, 高橋 英彦, 館農 勝, 中川 敦夫, 藤内 栄太, 森 貴俊, 諸隈 一平, 吉田 公輔, 早稲田 芳史  精神神経学雑誌  106-  (10)  1335  -1335  2004/10  [Not refereed][Not invited]
  • 宗谷地域における精神医療ネットワーク 市立稚内病院精神神経科の役割
    中島 幸治, 橋本 直樹, 栃木 昭彦, 朝倉 聡, 小山 司  精神神経学雑誌  106-  (8)  1075  -1075  2004/08  [Not refereed][Not invited]
  • 地域生活支援によって居宅生活を維持できた慢性期統合失調症患者の1例
    橋本 直樹, 栃木 昭彦, 中島 幸治, 朝倉 聡, 太田 洋一, 小山 司  精神神経学雑誌  106-  (8)  1075  -1075  2004/08  [Not refereed][Not invited]
  • 市立稚内病院精神神経科でのうつ病薬物療法における第一選択薬の推移
    橋本 直樹, 中島 幸治, 栃木 昭彦, 朝倉 聡, 北川 信樹, 小山 司  精神神経学雑誌  106-  (1)  109  -109  2004/01  [Not refereed][Not invited]

Research Projects

  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2021/04 -2024/03 
    Author : 久住 一郎, 石川 修平, 橋本 直樹, 扇谷 昌宏, 豊巻 敦人, 古賀 農人
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2020/04 -2023/03 
    Author : 橋本 直樹, 豊巻 敦人
     
    新規陰性症状評価尺度(Breif Negative Symptom Scale;BNSS)と、陰性症状のの生物学的基盤を評価する行動課題(The Effort Based Decision Making 課題 と、The Reward Based Learning 課題)について実施手順を整理した。社会認知機能の評価については、我々が別な研究で作成に関わった日本語版の新規社会認知機能評価尺度を本研究でも用いることに決め、インターネット上で遂行可能な検査 を構築し、検査マニュアルを作成した。自己の信念を評価するためのDefeatist Performance Belief(DPB)、社会機能の評価評価尺度であるSpecific Level of Functioning Scale (SLOF)についても使用準備を整えた。また、脳構造、脳機能の評価のために、脳の体積を高解像度T1強調画像(T1)、白質線維構 造を拡散強調画像(Diffusion tensor imaging, DTI)、安静時の機能的結合を安静時機能画像(resting state funbtionl MRI; rsfMRI)を大学病院のMRI装置 で撮像するべく、新しいMRI装置でのプロトコールを当院放射線科および他施設の研究者と相談しながら作成した。以上の準備ののちに、令和３年１１月よりリクルート、データ収集を開始した。現在まで、健常者12名、統合失調症患者40名のデータを取得している。
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2017/04 -2021/03 
    Author : Hashimoto Naoki
     
    We evaluate the reliability and validity of the Japanese versions of two new negative symptom rating scales, the Breif Negative Symptoms Scale (BNSS) and the Positive and Negative Syndrome Scale (PANSS). For the BNSS, we newly developed the Japanese version with the permission of the original author, and received certification. For the PANSS, we used the Structured Clinical Interview for the PANSS (SCI-PANSS) and the Informant Questionaire for the PANSS (Informant Questionnaire for the PANSS). High internal consistency, external validity, inter-rater reliability, and retest reliability were shown for both the BNSS and PANSS. The results of the Japanese BNSS factor analysis indicated a two-factor structure. We also developed the behavioral tasks (The Effort Based Decision Making task and The Reward Based Learning task) which assess the behavioral base of negative symptoms. However, due to the coronavirus pandemic, we only obtained data from six subjects.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2013/04 -2016/03 
    Author : OTSUKA Kotaro, SUZUKI Yuriko, FUJISAWA Daisuke, HASHIMOTO Naoki, KATO Takahiro, AOYAMA Kumi, YONEMOTO Naohiro, KOBARA Keiji, CHO Tetuji, SATO Ryoko
     
    We developed the structured educational program about the psychiatric knowledge, correspondence technique and spread in the supporters such as a healthcare worker engaged in community care and the mental health practitioner in this study and demonstrated an effect evaluation. We revised a program by the examination of the qualitative evaluation by the focus group in the study group and built the qualification system of the leader and built a system of a program offer and the information sharing by the IT.In the Japanese whole including a stricken area and job level, we got a base of the structure which widened a program ready in this study group.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2011 -2013 
    Author : KUSUMI Ichiro, ITO Koki, YOYOMAKI Atsuhito, HASHIMOTO Naoki
     
    The ratio of patients with at-risk mental state (ARMS) was 15.9% in 157 first-visit patients (16-30 y.o) at psychiatric clinic or hospitals in Hokkaido. Biological motion perception, neural response in endogenous rule shifting, and neural oscillations during Sternberg task in schizophrenia patients were significantly different from normal controls, which suggests that these markers are useful as endophenotypes of schizophrenia.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2010 -2012 
    Author : OTSUKA Kotaro, SUZUKI Yuriko, FUJISAWA Daisuke, YONEMOTO Naohiro, KATO Takahiro, HASHIMOTO Naoki, IWATO Sayaka, AOYAMA Kumi, SATO Ryoko, SUZUKI Shimako, KUROSAWA Mie, KAMISAKI Makoto
     
    We made the gatekeeper training program for medical care, mental health, educational staff and a family, in cooperation with Cabinet Office, Government of japan .We cooperated with Cabinet Office spreading these programs, and, in addition, offered facilitator training program.Also, we developed and conducted the Crisis intervention program of four mental disorder（depression, schizophrenia, anxiety disorders, substance dependence）in cooperation with an organization of the local mental health institution. And, we developed the facilitator program and tested and identified the efficacy.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2008 -2010 
    Author : KUSUMI Ichiro, SUZUKI Katsuji, KITAGAWA Nobuki, HASHIMOTO Naoki, TOYOMAKI Atsuhito
     
    It is possible that depressive patients have dysregulation of cognitive processes due to hyperactivity of anterior cingulate cortex. We measured feedback negativity, one of event-related brain potential and functional MRI during imposing decision-making and reward prediction problems, respectively. The amplitude of feedback negativity was decreased in schizophrenia patients compared to controls. Reward prediction induced increased neuronal activities in the dorsal anterior cingulate cortex and ventral striatum of healthy subjects using a functional MRI. Further studies are ongoing to evaluate these neurophysiological measures in depressed patients.

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.